

1 MAUREEN DONOVAN, Ph.D.

2 of pulmonary delivery in particular,
3 reproducibility was certainly important, and
4 there's always a question about even what's --
5 what amount of drug emitted from any device
6 what amount of that gets to the lungs. There's
7 loss between the device, the mouth, and then
8 subsequently the lungs, and many accept that
9 the ability to accurately know the exact amount
10 that got to the lungs is not something that we
11 use to evaluate or derive dosing strategies or
12 evaluate the particular system. It's the that
13 it was presented in a fashion that it could
14 have delivered the same amount each time the
15 device was used.

16 Q. Is there a teaching in Patton
17 on how long a patient needs to inhale after
18 they know that the bolus of medicine is ready
19 for inhalation?

20 A. My recollection is Patton
21 doesn't describe the time, but the device is
22 designed to contain -- the aerosol is emitted
23 into a volume that is a volume that a typical
24 user would be able to inhale under their use
25 conditions with a single inhalation. It's

1 MAUREEN DONOVAN, Ph.D.

2 based on lung volume, in essence, but if for
3 some patient it -- they weren't able to inhale
4 that volume, that the opportunity to follow up
5 with another breath is certainly part of the
6 device design based on the valve system.

7 The speed with which the
8 person inhales, you know, how fast they inhale,
9 whatever isn't described, and this device is
10 intended to potentially even limit some the
11 needs to specify those additional requirements
12 that were known as part of other devices at the
13 time.

14 Q. Does Patton disclose an
15 ultrasonic nebulizer?

16 A. It's not my recollection that
17 Patton included ultrasonic nebulizers. It's
18 certainly in his initial summary of the
19 invention he describes using a predetermined
20 volume of gas usually air as the material that
21 aerosolizes the drug-containing formulation,
22 but later in the patent I know that there is
23 other discussion of other ways to accomplish
24 some of the workings of the invention he is
25 describing, and I just don't remember among all

1 MAUREEN DONOVAN, Ph.D.
2 of the possible alternatives and directional
3 changes and so forth whether he opens or openly
4 describes that this might be further modified
5 for use with an ultrasonic system.

6 Q. Okay. My question might have
7 been too broad to be fair. So why don't we do
8 it this way.

9 If you could -- if I could
10 direct your attention to paragraph 90 of your
11 declaration. You state there that: "Patton
12 teaches a system that generates aerosol using
13 gas; i.e., a jet nebulizer."

14 So do you understand Patton to
15 be discussing the use of a jet nebulizer?

16 MR. MATHAS: Object to the form.

17 BY THE WITNESS:

18 A. Well, in the same way a jet
19 nebulizer uses a gas to form the aerosol that's
20 intended to be inhaled, Patton also primarily
21 describes the formation of an aerosol brought
22 forth by a volume of gas, usually a compressed
23 gas. So there -- that's where they are
24 similar.

25 The methodologies that

1 MAUREEN DONOVAN, Ph.D.

2 traditional jet nebulizers use to form aerosols
3 are not the same methodologies that Patton's
4 description uses to form the aerosol.

5 Q. I am not sure I understand.

6 So are you saying that Patton
7 does not teach the use of a jet nebulizer?

8 A. No, I am saying that both jet
9 nebulizers and Patton's invention description
10 describe using a gas, typically a compressed
11 gas to form the aerosol. That's their
12 similarity. The mechanism by which a jet
13 nebulizer -- the traditional jet nebulizers
14 form that aerosol is different than the
15 mechanism by which the aerosol is formed by the
16 gas described in the invention described in
17 Patton.

18 Q. Got it. Okay. And neither a
19 traditional jet nebulizer or the device that's
20 taught in Patton is an ultrasonic nebulizer,
21 correct?

22 A. As described in this paragraph
23 what I mean by jet nebulizer, no, there's not
24 an ultrasonic source, a sound source that's
25 forming the aerosol, nor in most of the

1 MAUREEN DONOVAN, Ph.D.

2 description in Patton does he describe using an
3 ultrasonic power or an ultrasonic energy source
4 to form the aerosol.

5 Q. You said most of the
6 description in Patton does not describe using
7 an ultrasonic power energy source.

8 Is there any discussion in
9 Patton that does talk about ultrasonic power?

10 A. Again, I don't recall all of
11 the details regarding other aspects of the
12 invention. So I just don't know whether the
13 word ultrasonic or ultrasound appears anywhere
14 in the patent document, but it's certainly not
15 the original design of the invention that's
16 being described primarily in the document.

17 Q. So we have been going 21
18 minutes since we last talked about breaking.
19 Is this a good time to break?

20 A. It's a good time for me.

21 THE VIDEOGRAPHER: Going off the
22 record. The time is 12:17 p.m.

23 (WHEREUPON, a recess was had at
24 12:17 p.m. until 1:23 p.m.)

25 THE VIDEOGRAPHER: Going on the

1 MAUREEN DONOVAN, Ph.D.

2 record. This marks the beginning of media
3 number 3. The time is now 1:23 p.m.

4 BY MS. ASCARRUNZ:

5 Q. Dr. Donovan, when we were
6 discussing Patton, I think we talked about the
7 use of a compressor, correct?

8 A. We were talking about
9 compressed air and jets, yes.

10 Q. Okay. And it's your opinion
11 that Patton teaches the use of a light and
12 sound that is -- that meets the claim
13 limitation for an opto-acoustical trigger,
14 correct?

15 A. Well, it has a light device, a
16 sound device that signals the user. So, yes,
17 it's an opto-acoustic device.

18 Q. Okay. And do you consider it
19 to be an opto-acoustical trigger?

20 A. Well, it's a device that has a
21 light and a sound. They have a meaning to the
22 user based on the instructions, and so if you
23 want to call that an opto-acoustic trigger, it
24 can be viewed as an opto-acoustic trigger under
25 that set of conditions.

1 MAUREEN DONOVAN, Ph.D.

2 Q. Okay. I will come back to
3 that.

4 The light and the sound comes
5 on immediately after the operation of the
6 compressor ceases, correct?

7 A. That's how it's described,
8 yes.

9 Q. You agree with me that all of
10 the claims of both patents require an
11 opto-acoustical trigger, right?

12 A. Well, based in the description
13 in claim 1 that describes a pulsed ultrasonic
14 nebulizer that aerosolizes -- oh, next one
15 second --

16 THE COURT REPORTER: Wait, I'm
17 sorry.

18 BY THE WITNESS:

19 A. I'm sorry. Said pulsed
20 ultrasonic nebulizer comprising an
21 opto-acoustic trigger as stated in claim 1 of
22 both patents, and the fact that all of the rest
23 of the claims are dependent to claim 1, there's
24 a requirement for an opto-acoustic trigger.

25

1 MAUREEN DONOVAN, Ph.D.

2 BY MS. ASCARRUNZ:

3 Q. Okay. And that applies to
4 both patents, correct?

5 A. It's my interpretation because
6 of the dependency of the rest of the claims,
7 yes.

8 Q. Do you agree with me that the
9 word trigger must itself mean something in the
10 claims?

11 MR. MATHAS: Object to the form.

12 BY THE WITNESS:

13 A. I don't think so. I don't
14 recall in the specification where trigger is
15 specifically defined in the terminology of the
16 patent writer.

17 BY MS. ASCARRUNZ:

18 Q. Okay. So let me ask it this
19 way.

20 Let's look at the '507 patent,
21 and you see that claim 1 claims a kit for
22 treating pulmonary hypertension comprising, and
23 then has several paragraphs following?

24 A. Okay.

25 Q. The section labeled Romanette

1 MAUREEN DONOVAN, Ph.D.

2 ii reads: "A pulsed ultrasonic nebulizer
3 comprising an opto-acoustical trigger."

4 Do you agree with me that
5 claim 1 and, therefore, all claims of this
6 patent by dependency require a pulsed
7 ultrasonic nebulizer comprising an
8 opto-acoustical trigger?

9 A. I agree that that's what's
10 stated in claim 1, Roman Numeral II.

11 Q. The word trigger in that claim
12 language, what does that mean to a person of
13 ordinary skill in the art?

14 A. I think the best synonym for
15 that for a POSA would be the word indicator.

16 Q. And it's your opinion that
17 Patton expressly teaches the need and function
18 of an opto-acoustical trigger, right?

19 A. Well, Patton describes the
20 usage of an opto-acoustic indicator in the
21 device that he has designed as a way of
22 demonstrating that the aerosol containing the
23 medicament has been placed into the chamber.

24 Q. The word trigger doesn't carry
25 a specific -- it's not a term of art that's

1 MAUREEN DONOVAN, Ph.D.

2 used in the art of inhalation therapies,
3 correct?

4 A. Not in the art that I am most
5 familiar, no.

6 Q. Okay. And it's your opinion
7 that, as used in the claims, the word trigger
8 is synonymous with indicator?

9 A. That's the way -- that's the
10 synonym I use for that word, and I anticipate a
11 number of other POSAs would use that term also
12 or use that synonym also.

13 Q. So in your opinion is any
14 signal that would demonstrate to the patient
15 that a device is ready for the patient to
16 inhale is a trigger within the meaning of the
17 claims?

18 MR. MATHAS: Object to the form.

19 BY THE WITNESS:

20 A. That can either -- restate
21 that. I am going to have to ask you to break
22 that down.

23 BY MS. ASCARRUNZ:

24 Q. Okay. In your opinion is a --
25 is an indicator that demonstrates to the

1 MAUREEN DONOVAN, Ph.D.

2 patient that a device is ready for the patient
3 to inhale is a trigger within the meaning of
4 the claims?

5 MR. MATHAS: Same objection.

6 BY THE WITNESS:

7 A. Well, I think, as I stated,
8 when I read the descriptor for Roman Numeral
9 II, my interpretation of the meaning of that is
10 I could substitute the word indicator for
11 trigger. That that was the intended meaning
12 and no further meaning implied to some term the
13 word used trigger.

14 BY MS. ASCARRUNZ:

15 Q. Okay. Since we were focusing
16 on the '507 patent, can I ask is it also your
17 opinion with respect to the word trigger in the
18 '240 patent that you could substitute the word
19 trigger for indicator and that would cover the
20 intended meaning of the word?

21 A. The phrase in the '240 patent
22 is different than the phrase in the '507. So
23 in this case said pulsed ultrasonic nebulizer
24 comprising an opto-acoustic trigger which
25 allows said human to synchronize each breath to

1 MAUREEN DONOVAN, Ph.D.

2 each pulse, and in the case of this phrase
3 within this claim, yes, as a POSA, my equal
4 interpretation to the word trigger is
5 indicator.

6 Q. Okay. In paragraph 125 of
7 your '240 declaration, you state that: "A POSA
8 would be motivated to combine Voswinckel's
9 teaching of a therapeutically efficacious
10 treatment using a pulse nebulizer with Patton's
11 teachings on reliability, precision, and
12 efficiency."

13 Do you see that?

14 A. Yes.

15 Q. Why would a POSA be motivated
16 to combine those two references in that way?

17 A. Well, because at the time it
18 was well known in the art that there were human
19 factors involved in the therapeutic efficacy of
20 inhaled dosage forms, and there was a
21 motivation to try to make the devices that were
22 being used as -- as obvious and easy for
23 patients to use them correctly as possible.
24 And so including additional indicators that
25 allowed the patient to use the device as

1 MAUREEN DONOVAN, Ph.D.

2 designed was a motivation for everybody
3 involved in pulmonary device development at the
4 time.

5 Q. Okay. Is there any statement
6 in Voswinckel itself that provides a specific
7 motivation to modify the nebulizer disclosed?

8 MR. MATHAS: Object to the form.

9 BY THE WITNESS:

10 A. Well, there's nothing specific
11 in the Circulation abstract, but even comparing
12 the European Heart Journal abstract to the
13 Circulation abstract, it's obvious that the --
14 that Voswinckel changed nebulizers. So he was
15 certainly aware that one could select a
16 different nebulizer for whatever purpose one
17 needed to during a -- you know, during a series
18 of investigations.

19 So it doesn't expressly state
20 that, but I think there's a clear indication
21 that by just comparing those two abstracts,
22 that Voswinckel and certainly others in the art
23 were open to selecting a device where they were
24 confident that that device was accomplishing
25 what they desired for patient treatment.

1 MAUREEN DONOVAN, Ph.D.

2 BY MS. ASCARRUNZ:

3 Q. Okay. So you referred to the
4 European Heart Journal abstract, and what I am
5 trying to do is focus just on your statement in
6 paragraph 125 about a motivation to combine
7 Voswinckel's teachings with Patton's teachings.

8 So -- and I understand your
9 testimony that you believe there are human
10 factor considerations that a POSA would
11 consider that would guide the motivation to
12 combine those teachings in particular ways.
13 Did I understand your testimony correctly?

14 A. Yes.

15 Q. What I am trying to understand
16 is is there a statement in either of those two
17 references explicitly in Voswinckel or in
18 Patton that motivates a person of ordinary
19 skill in the art to modify one or the other to
20 arrive at the invention that is claimed in the
21 patents at issue?

22 MR. MATHAS: Object to the form.

23 BY THE WITNESS:

24 A. Well, again, a POSA is -- is
25 aware of the activities surrounding device

1 MAUREEN DONOVAN, Ph.D.

2 development for inhalation delivery, and
3 certainly understood the teachings of Patton
4 and some of the -- both the technology to form
5 the aerosol and other portions of the device
6 that Patton describes and their attributes and
7 understands the attributes of other devices,
8 some of which were more readily available
9 potentially in particular regions.

10 And as a result, there's a
11 motivation from the POSA to always try to --
12 try to identify some of the best qualities of
13 the art at the time and include them in a next
14 stage in this case we are talking about
15 devices.

16 BY MS. ASCARRUNZ:

17 Q. Okay. So I understand you
18 said there's a motivation from the POSA to
19 always try to identify the best qualities of
20 the art at the time, but my question is you
21 don't identify an explicit statement in either
22 of Voswinckel or Patton that directly invites a
23 POSA to modify the teachings to combine them;
24 is that right?

25 MR. MATHAS: Object to the form.

1 MAUREEN DONOVAN, Ph.D.

2 BY THE WITNESS:

3 A. Well, the POSA would realize
4 that the OptiNeb nebulizer family already had
5 the physical capabilities to have an
6 opto-acoustic trigger, and the device described
7 in Patton describes that as a component of the
8 device. And the POSA essentially is learning
9 from Patton that -- and knew this likely even
10 before Patton described it in the specific --
11 in the specific patent based on the fact that
12 there were other devices available that used --
13 used lights, used sounds, used other things to
14 indicate to patients how to use the device
15 appropriately.

16 So the motivation is that
17 Patton describes using light and sound to
18 indicate something about the dose being ready
19 for the patient, and that's easily transferable
20 to a different device that is easily capable of
21 using those same sensory readouts to improve
22 the ability of a patient to use that device
23 correctly.

24 BY MS. ASCARRUNZ:

25 Q. I understand your testimony.

1 MAUREEN DONOVAN, Ph.D.

2 I do. But that wasn't the question that I
3 asked. So let me go about it this way.

4 Can you point to a statement
5 in the Voswinckel reference that invites a POSA
6 to modify the device used in that reference in
7 any way?

8 MR. MATHAS: Object to the form.

9 BY THE WITNESS:

10 A. Again, the Voswinckel
11 Circulation abstract is merely an abstract.
12 It's a very abbreviated form of information
13 that's being presented, but even in its very
14 abbreviated form when I compare it to a similar
15 abstract by a similar group of investigators, I
16 already see that they have changed the
17 nebulizer from a continuous nebulizer to a
18 pulse nebulizer.

19 It tells me that they are open
20 to the opportunity of improvements or changes
21 in a nebulizer to advantage some
22 characteristics of those nebulizers for
23 improved patient therapy, and knowing that
24 there are other improvements from a human
25 factors standpoint that could yet again improve

1 MAUREEN DONOVAN, Ph.D.
2 the usefulness, the ability of patients to use
3 the nebulizers correctly in an outpatient
4 setting, not in the acute care setting that was
5 described in the Voswinckel Circulation
6 abstract, certainly there's a motivation to
7 provide the -- the invention or the -- provide
8 the best possible characteristics in any
9 nebulizer to provide to a set of patients who
10 are in need of a reproducible, accurate,
11 at-home nebulizer system for an important
12 therapy.

13 BY MS. ASCARRUNZ:

14 Q. Is that motivation made
15 explicit in the text of Voswinckel?

16 MR. MATHAS: Object to the form.

17 BY THE WITNESS:

18 A. Again, a POSA doesn't need a
19 specific text to direct them to --

20 BY MS. ASCARRUNZ:

21 Q. And that wasn't my question.
22 My question was --

23 MR. MATHAS: Veronica, you have to
24 let her answer. Then you can ask your question
25 again if you don't like her answer.

1 MAUREEN DONOVAN, Ph.D.

2 BY THE WITNESS:

3 A. So, again, a POSA doesn't need
4 specific direction to take known information in
5 the art and utilize it and combine it, and
6 whether there's something actually specifically
7 in an abstract an abbreviated description of a
8 body of work that suggests that or not, that --
9 a POSA doesn't need that.

10 BY MS. ASCARRUNZ:

11 Q. I understand that. I'm asking
12 the question whether -- so I understand that
13 it's your testimony that a POSA did have a
14 motivation to combine those two references as
15 you have indicated, and you've testified at
16 length as to where you believe that motivation
17 would reside in the considerations of a POSA.

18 Is that a fair
19 characterization of your testimony?

20 A. Yes.

21 Q. Okay. All I am trying to
22 establish is that that motivation was in the
23 mind-set and considerations of a POSA and not
24 in a sentence in one of these references. So I
25 am asking you to identify is there a sentence

1 MAUREEN DONOVAN, Ph.D.

2 in Voswinckel that provides a motivation to
3 modify the device used in Voswinckel?

4 MR. MATHAS: Asked and answered.

5 BY THE WITNESS:

6 A. There's not a specific
7 sentence that -- in the Voswinckel Circulation
8 abstract that describes anything about needing
9 or desiring to change the device in their
10 future studies. It doesn't necessarily mean
11 that they -- they hadn't or another POSA
12 wouldn't contemplate doing that.

13 BY MS. ASCARRUNZ:

14 Q. Okay. Is there a specific
15 statement or sentence in the Patton reference
16 that invites a POSA to use the features
17 described for the treatment of pulmonary
18 hypertension?

19 A. Well, again, Patton is open to
20 the use of the device described in the '951
21 patent application or however we want to refer
22 to that. That his device provides a method to
23 deliver a medicament by inhalation to reach the
24 lungs of the patient which means that to a POSA
25 that any treatment that a POSA would need to

1 MAUREEN DONOVAN, Ph.D.

2 reach the lungs to achieve the treatment goal
3 that the Patton device is capable of being
4 utilized to do that.

5 (Reporter Clarification.)

6 BY MS. ASCARRUNZ:

7 Q. Earlier in your discussion of
8 a POSA being motivated to modify the device
9 used in Voswinckel, you referred to the
10 Voswinckel Exhibit 1047 reference.

11 Do you recall that discussion?

12 A. I think I need to be reminded
13 what the Voswinckel 1047 reference is.

14 Q. Sometimes we refer to it as
15 Voswinckel II, but it's the European Heart
16 Journal.

17 A. Okay. Can I take a look at
18 that reference?

19 MR. MATHAS: 1046?

20 BY MS. ASCARRUNZ:

21 Q. Did I -- sorry, 1046.

22 A. So it's European Heart Journal
23 abstract.

24 Q. Yes.

25 A. Okay. Yes. All right.

1 MAUREEN DONOVAN, Ph.D.

2 Q. So when I asked you about the
3 motivation in Voswinckel to modify the device,
4 you told -- you referred me to this other
5 Voswinckel reference and said that it tells you
6 that they are open to the opportunity of
7 improvements or changes in a nebulizer to
8 advantage some characteristics of those
9 nebulizers for improved patient therapy.

10 Do you recall that testimony?

11 A. Yes.

12 Q. What does this reference which
13 I will start referring to as Voswinckel II just
14 for clarity of the record, tell you about the
15 willingness of the investigators to improve --
16 to make improvements or changes to the
17 nebulizer?

18 A. Well, the Voswinckel II
19 abstract describes the use of an OptiNeb
20 ultrasound nebulizer and a six-minute
21 inhalation exposure, and the Voswinckel
22 American Heart Association abstract describes
23 using three single breaths from a pulsed
24 OptiNeb ultrasonic nebulizer, and it was
25 certainly very well known in the field for

1 MAUREEN DONOVAN, Ph.D.

2 nebulizer therapy that reducing the amount of
3 time to achieve the dose needed for a patient
4 was an important aspect of nebulizer therapy
5 and patient adherence to nebulizer therapy.

6 So moving from a six-minute
7 nebulization to a three inhalation therapy
8 whether that was accomplished exactly by a
9 change in nebulizer or accomplished by other
10 activities in addition was certainly something
11 that Voswinckel demonstrates that groups were
12 aware of and were in relatively similar
13 timeframes evaluating the opportunity to use a
14 device that provided a better user experience.

15 Q. Okay. Now, you are aware that
16 the single ground that the Board instituted for
17 decision in this trial was the question --
18 speaking just to the '240 patent, was limited
19 to the question of obviousness over Voswinckel
20 in view of Patton and Ghofrani, correct?

21 A. In the '240 patent, yes.

22 Q. But it's your opinion that in
23 part a motivation to combine those references
24 is evidenced by Voswinckel II, correct?

25 A. No, I don't need Voswinckel

1 MAUREEN DONOVAN, Ph.D.

2 II, but you were asking directly about specific
3 statements in Voswinckel I, and because it's an
4 abstract, it's a very short description of work
5 conducted and has often times very little
6 description about what other information the
7 authors are thinking, and so I look to other
8 evidence even from the same group to
9 demonstrate that, yes, those other -- those
10 investigators were thinking about other things
11 to improve this therapy beyond just the mere
12 words that are included in the written
13 description in the abstract.

14 And so I don't need to rely on
15 Voswinckel II to come to the -- to come to the
16 opinions that I did in the matter of the '507
17 or '240 patents. Merely use that as an obvious
18 example of even whether it's -- whether
19 something is actually stated clearly in an
20 abstract. It was clear that even that same
21 research group understood that that was a
22 consideration and a motivation.

23 Q. Okay. So because Voswinckel I
24 is an abstract and it's a very short
25 description of work conducted and has often

1 MAUREEN DONOVAN, Ph.D.

2 times very little description about what other
3 information the authors are thinking, you
4 looked to Voswinckel II to supplement that
5 understanding, correct?

6 MR. MATHAS: Object to the form.

7 BY THE WITNESS:

8 A. No, that's not correct. I
9 didn't need to look to Voswinckel II. We
10 started discussing Voswinckel II because I was
11 answering questions you were asking about
12 specific statements included in the Voswinckel
13 I abstract that would have described the
14 author's thoughts, desires, I don't remember
15 the wording about the nebulizer, and I provided
16 you with actual evidence of what would be clear
17 to a POSA that there -- that those
18 investigators must have been thinking about
19 issues regarding modifying the nebulizers being
20 used because they demonstrated that they even
21 did that in order to modify the dosing regimen
22 that they used that was different between those
23 two, but I don't need to rely on Voswinckel II
24 for that. I was using that as an example to
25 answer your questions.

1 MAUREEN DONOVAN, Ph.D.

2 BY MS. ASCARRUNZ:

3 Q. Do you need to refer to
4 Voswinckel II to understand the motivation of
5 the Voswinckel I authors to modify the device
6 disclosed therein?

7 MR. MATHAS: Object to the form.

8 BY THE WITNESS:

9 A. No. Again, a POSA understood
10 that certainly at the time of the priority date
11 of the '240 and the '507 patents it was well
12 known that in evaluating human factors and
13 improving the human interface with devices was
14 an important thing to do in order to improve
15 user -- improve the use of the device, improve
16 the adherence to the design dosing strategies
17 and so forth.

18 It was -- POSA's were well
19 aware of those issues and were motivated to try
20 to find ways to improve devices to address
21 human factors issues and improve patient
22 interactions with devices.

23 BY MS. ASCARRUNZ:

24 Q. Okay. Where in Voswinckel I
25 is it said that three breaths are delivered in

1 MAUREEN DONOVAN, Ph.D.

2 less than six minutes?

3 A. It doesn't -- let's see.
4 Voswinckel I doesn't specifically indicate the
5 timeframe over which the three breaths were
6 taken, but a POSA reading this and, again, if
7 it was -- if the occurrence or the
8 description -- start over.

9 If the methodology used by the
10 investigators was going to differ significantly
11 from what a reader of this abstract would be
12 expected to understand, the authors typically
13 make additional -- put in additional
14 information into the abstract. So those
15 methods are clear.

16 So not having additional
17 information indicates that a POSA is free to
18 believe that this medication was dosed in the
19 same way you would dose other medications with
20 the OptiNeb ultrasound nebulizer which means
21 three single breaths receiving the dose over a
22 relatively short interval of time, certainly
23 far less than six minutes.

24 Q. Okay. We were talking about
25 paragraph 125, and the last sentence there you

1 MAUREEN DONOVAN, Ph.D.

2 indicate: "A POSA would have a reasonable
3 expectation of success with such a
4 combination," which refers to the combination
5 of Voswinckel and Patton, "because it simply
6 seeks to improve upon the successful treatment
7 already achieved."

8 Do you see that?

9 A. I see that.

10 Q. Why would a POSA seek to
11 improve a treatment that is already
12 successful?

13 A. Because while the treatment
14 was therapeutically successful, the future of
15 the treatment was having patients be able to
16 use that treatment in -- and, you know, not
17 have it be a lifestyle interference. So in
18 addition to being able to demonstrate that it
19 was a successful treatment in the acute study
20 or even with the two patients who were using it
21 for compassionate use, there's a -- there's a
22 motivation to make improvements so that when
23 that is sent out into patients using it in
24 their homes and other situations, that again
25 it's as easy as possible for them to adhere to

1 MAUREEN DONOVAN, Ph.D.
2 the therapeutic regimen. And for the
3 alterations to -- and the need to take Patton's
4 teaching about an optical and sound based
5 indicator and combine that, a POSA wouldn't --
6 would have every expectation that that could be
7 achieved.

8 Q. You reviewed the file
9 histories of both patents at issue, correct?

10 A. I did quite a while ago, yes.

11 Q. Do you recall reviewing the
12 declarations of -- of a Dr. Rubin?

13 A. I -- only vaguely. I know I
14 speak to it in my report, but I would need to
15 see that declaration again to remind myself
16 what it said.

17 Q. Do you recall reviewing the
18 declaration of a Dr. Zamanian?

19 A. Again, I think I recall. I
20 mean, I know there was something about material
21 provided by Dr. Zamanian, but I don't recall in
22 what aspects.

23 Q. Okay. Do you recall reviewing
24 a declaration of a Dr. Elder?

25 A. I'm not sure. It's been a

1 MAUREEN DONOVAN, Ph.D.

2 very long time since I have looked at those
3 file histories.

4 Q. And you recalled that you may
5 have discussed Dr. Rubin's declaration
6 somewhere in your declaration, correct?

7 A. I thought that I did. Yes, in
8 paragraph 210 in the '240 declaration, I
9 mention what I understood Dr. Rubin's
10 declaration to communicate.

11 Q. And what did you understand
12 that to be?

13 A. Well, Dr. Rubin was -- I think
14 it's -- I can only summarize essentially what's
15 in this paragraph. I think -- I am sure
16 there's more in the declaration I should speak
17 to. So I would like to review it briefly.

18 Q. In the course of forming your
19 opinions in this case, did you at any point
20 form an opinion that Dr. Rubin's declaration
21 and the file histories was not credible?

22 MR. MATHAS: Object to the form.

23 BY THE WITNESS:

24 A. Again, it's been a long time
25 since I have reviewed the file history or the

1 MAUREEN DONOVAN, Ph.D.

2 declarations. So I would need to refresh my
3 memory about what that specific declaration
4 said and whether there were other things I
5 evaluated as I read that.

6 BY MS. ASCARRUNZ:

7 Q. Well, certainly nowhere in
8 your declaration did you articulate an opinion
9 that Dr. Rubin is not credible, correct?

10 A. No, I did not communicate that
11 in my declaration.

12 Q. Did you communicate anywhere
13 in your declaration that Dr. Zamanian is not
14 credible?

15 A. I don't know that I recall
16 that there's a description of Dr. Zamanian's
17 declarations in this report.

18 Q. Okay. Are you aware that both
19 Drs. Rubin and Dr. Zamanian are medical doctors
20 with an expertise in treating patients with
21 pulmonary hypertension?

22 A. I think people have told me
23 that that's their background.

24 Q. You don't claim to know more
25 than Dr. Rubin or Dr. Zamanian regarding the

1 MAUREEN DONOVAN, Ph.D.

2 medical treatment of pulmonary hypertension,
3 correct?

4 A. That's correct.

5 Q. And you don't claim to know
6 more than Dr. Rubin or Dr. Zamanian regarding
7 patient responses to the treatment of pulmonary
8 hypertension with inhaled treprostinil,
9 correct?

10 A. Clinically observable patient
11 responses?

12 Q. Yes.

13 A. No, I don't know more than
14 those two physicians, no.

15 Q. You are aware that there's a
16 consideration in this case as one of the
17 objective indicia as to whether or not TYVASO
18 is commercially successful, correct?

19 A. I understand that that's
20 certainly part of the case, yes.

21 Q. And you are aware that TYVASO
22 has been sold on the market since its approval
23 by the FDA, correct?

24 A. That's -- I mean, that's my
25 assumption. I haven't tracked any time that it

1 MAUREEN DONOVAN, Ph.D.
2 had been in shortage or not available.

3 Q. Okay. And you agree that the
4 attributes of TYVASO that drive its sales
5 include the frequency of its administration,
6 its shorter duration of treatment time as
7 compared to Ventavis, and its efficacy,
8 correct?

9 MR. MATHAS: Object to the form.

10 BY THE WITNESS:

11 A. Can you restate that question?

12 BY MS. ASCARRUNZ:

13 Q. Yes.

14 A. Or at least reread it.

15 Q. Do you agree that the
16 attributes of TYVASO that drive its sales
17 include the frequency of its administration,
18 its shorter duration treatment time as compared
19 to Ventavis, and its efficacy?

20 MR. MATHAS: Same objection.

21 BY THE WITNESS:

22 A. Well, I understand that there
23 are differences between TYVASO and other
24 pulmonary inhalation products for pulmonary
25 hypertension that allow TYVASO to have

1 MAUREEN DONOVAN, Ph.D.

2 administration characteristics that might be
3 preferred by patient users. It is well known
4 that treprostinil was particularly pulmonary
5 selective. The half life of TYVASO provides
6 or -- provides the opportunity to have a longer
7 duration between administrations. The ability
8 of -- to formulate TYVASO or treprostinil at a
9 concentration that allows a reduced number of
10 inhalations allow the product known as TYVASO
11 to have the characteristics it has.

12 Q. Let me ask you about paragraph
13 213 of your '240 declaration. The first
14 sentence of paragraph 213 you state: "I
15 understand that the examiner rejected each and
16 every one of these secondary consideration
17 arguments, and I agree especially in light of
18 the teachings of Voswinckel and Ghofrani."

19 Do you see that?

20 A. I see that.

21 Q. And you don't cite any
22 particular portion of the file history for that
23 statement, correct?

24 A. I didn't cite it in this
25 particular paragraph, no.

1 MAUREEN DONOVAN, Ph.D.

2 Q. Did you have in mind when you
3 wrote this sentence where the examiner rejected
4 each and every one of the patent owner's
5 secondary consideration arguments?

6 A. Again, I don't recall a
7 specific section because, again, it's been a
8 really long time since I looked at the file
9 histories. I don't remember the sequence of
10 rejections and responses and final
11 determinations.

12 Q. Okay. But do you stand by the
13 statement that the examiner rejected each and
14 every one of the patent owner's secondary
15 consideration arguments?

16 A. In the absence of being able
17 to review the file history, yes. I believe
18 that my understanding of the record as I read
19 it and wrote my report is that the examiner
20 rejected each and every one of the secondary
21 considerations arguments.

22 Q. And do you know with respect
23 to what claims the examiner rejected such
24 arguments?

25 A. I have no recollection on the

1 MAUREEN DONOVAN, Ph.D.

2 details of the -- again, the rejections and the
3 responses and the rejections and the responses
4 that are part of the file histories.

5 Q. You are obviously aware that
6 some claims issued in both of the patents that
7 are at issue in this case in the IPR
8 proceedings, correct?

9 A. Well, that there are claims
10 issued for the '507 patent and the '240 patent.
11 So, yes, some claims issued.

12 Q. And that necessarily means the
13 examiner found those claims to be non-obvious,
14 correct?

15 MR. MATHAS: Object to the form.

16 BY THE WITNESS:

17 A. Again, those claims issued,
18 but exactly what the patent examiner evaluated,
19 how they made their determination to issue
20 those is beyond my ability to comment on.

21 BY MS. ASCARRUNZ:

22 Q. And that includes the
23 examiner's opinions with respect to objective
24 indicia, correct?

25 MR. MATHAS: Same objection.

1 MAUREEN DONOVAN, Ph.D.

2 BY THE WITNESS:

3 A. The claims issued. That's
4 what I understand.

5 BY MS. ASCARRUNZ:

6 Q. I want to go back to our
7 discussion about the word pulsed, and before we
8 do that, let's maybe set the context and have
9 both of the two patents at issue in front of
10 you.

11 And looking to the '240
12 patent -- the '240 patent, do you agree with me
13 that a requirement of the claims includes the
14 use of a quote "pulsed ultrasonic nebulizer"?

15 A. Yes, in both claim 1 -- claim
16 1 in both the '240 and the '507 include the
17 phrase pulsed ultrasonic nebulizer, and a POSA
18 would understand that term to mean an
19 ultrasonic nebulizer that's capable of
20 delivering the aerosols in a pulsed manner.

21 Q. So your understanding of the
22 word pulsed in the context of the claims of
23 both patents is that it is -- that the phrase
24 pulsed ultrasonic nebulizer means an ultrasonic
25 nebulizer that is capable of delivering the

1 MAUREEN DONOVAN, Ph.D.

2 aerosols in a pulsed manner, correct?

3 A. Well, as I -- you know, as we
4 read the remaining description about the pulsed
5 ultrasonic nebulizer in claim 1, and I am
6 looking at the '240 patent, it's requiring it
7 to be able to deliver a fixed amount of
8 treprostiniol or pharmaceutically acceptable
9 salt. So that fixed amount indicates that it's
10 being delivered as a pulse where there's a
11 pause in time where there's not delivery
12 happening.

13 Q. In your reading of the claim,
14 does it indicate how long that period of time
15 is when there is a pause in time when there is
16 not delivery happening?

17 A. No, I don't read anything into
18 the claim regarding the amount of -- the length
19 of the time interval.

20 Q. And there's nothing else in
21 the claim that describes to you the length of
22 the time interval?

23 A. Well, later in the claim it
24 describes the number of breaths that might be
25 used to administer a particular mass of the

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

MAUREEN DONOVAN, Ph.D.

drug treprostnil, and depending on what sequence of breaths somebody wanted to take, that indicates a possible amount of time that the total administration might take, but there's nothing within the claim that describes the specific length of time of the pulse.

Q. Okay. Focusing again on the use of the word pulse in the claims and not just speaking in the abstract general English terminology, but focusing on the use of the word pulsed in the claims, is it your opinion that an ultrasonic nebulizer with a constant output that has a switch you can use to turn the device on and off can be a pulsed ultrasonic nebulizer within the meaning of the claims?

MR. MATHAS: Object to the form.

BY THE WITNESS:

A. I believe that an ultrasonic nebulizer that's capable of administering a fixed amount of the drug and then not -- not continue to aerosolized could be viewed as a pulsed ultrasonic nebulizer.

1 MAUREEN DONOVAN, Ph.D.

2 BY MS. ASCARRUNZ:

3 Q. Is it your opinion that an
4 ultrasonic nebulizer with a constant output
5 that has a switch you can use to turn the
6 device on and off can be a pulsed ultrasonic
7 nebulizer within the meaning of the claims?

8 MR. MATHAS: Same objection.

9 BY THE WITNESS:

10 A. That same -- if the turning
11 the switch off can discontinue the aerosol
12 production and then switching the -- switching
13 the nebulizer back on in whatever timeframe it
14 is that is desired or required that delivers
15 two pulses or if you switch it off again, it
16 will deliver -- and switch it back on again, it
17 will deliver three pulses of the medication.

18 BY MS. ASCARRUNZ:

19 Q. And in that instance then that
20 would fall within the meaning of pulsed
21 ultrasonic nebulizer in the claims?

22 A. Well, because it's
23 aerosolizing a fixed amount of treprostinil,
24 yes.

25 Q. Is it your opinion that an

1 MAUREEN DONOVAN, Ph.D.

2 ultrasonic nebulizer with a timed uninterrupted
3 stream of aerosol that lasts for ten seconds is
4 a pulsed ultrasonic nebulizer?

5 MR. MATHAS: Object to the form.

6 BY THE WITNESS:

7 A. As long as the amount of
8 aerosol is reproducible during the time that
9 the aerosol is being produced and that there's
10 a period of time where the aerosol is not being
11 produced, that could be considered a pulsed
12 delivery.

13 BY MS. ASCARRUNZ:

14 Q. Can a pulse within the meaning
15 of the claims last more than one breath?

16 A. I don't see anything in the
17 claims that indicates that there's a time
18 duration requirement for the time between
19 pulses. So there could be -- there could be
20 other breaths between the breaths being used to
21 inhale the aerosol.

22 Q. Okay. If a device has
23 intermittent periods of aerosol generation and
24 no aerosol generation, would this be pulsed
25 according to your understanding of the use of

1 MAUREEN DONOVAN, Ph.D.

2 the terminology in the claims?

3 A. Can you repeat that, please?

4 Q. Sure. If a device has
5 intermittent periods of aerosol generation and
6 no aerosol generation, would this be pulsed
7 within the meaning of the claims?

8 MR. MATHAS: Object to the form.

9 BY THE WITNESS:

10 A. I am still confused. One more
11 time.

12 BY MS. ASCARRUNZ:

13 Q. Would it be considered pulsed
14 within the meaning of the claims if a device
15 were to have intermittent periods of aerosol
16 generation and no aerosol generation?

17 So it switches back and forth
18 from aerosol generation, no aerosol generation,
19 aerosol generation, no aerosol generation.

20 MR. MATHAS: Object to the form.

21 BY THE WITNESS:

22 A. Yes, I believe that is within
23 the definition of pulsed delivery from an
24 ultrasonic nebulizer.

25

1 MAUREEN DONOVAN, Ph.D.

2 BY MS. ASCARRUNZ:

3 Q. Okay. If a device is turned
4 on to generate aerosol, turned off to cease the
5 aerosol generation, put down, and then turned
6 on again after a period of time to generate
7 aerosol, would this be pulsed according to the
8 meaning of the claims?

9 MR. MATHAS: Object to the form.

10 BY THE WITNESS:

11 A. It -- I would certainly
12 consider it could be. There -- there are a
13 number of different ways that someone might
14 configure an ultrasonic nebulizer and a
15 solution of drug and the need of a particular
16 patient or group of patients or whatever that
17 conceivably might include a longer non-aerosol
18 generation period.

19 BY MS. ASCARRUNZ:

20 Q. Are you familiar with the term
21 breath actuated in the art of inhalation
22 therapy?

23 A. Yes, I am.

24 Q. If a device generates
25 aerosol -- okay. In a breath-actuated device

1 MAUREEN DONOVAN, Ph.D.

2 where the device delivers aerosol to the
3 patient due to the patient's breathing -- I'm
4 sorry. Let me start all over.

5 Can a breath-actuated device
6 be a pulsed device within the meaning of the
7 claims?

8 MR. MATHAS: Object to the form.

9 BY THE WITNESS:

10 A. It depends. If that breath
11 actuated device is capable of or is designed to
12 deliver that fixed amount regardless of the
13 other factors in the patient inhalation, yes,
14 it could be considered if it uses ultrasonic --
15 a pulsed ultrasonic device.

16 BY MS. ASCARRUNZ:

17 Q. And when you say regardless of
18 the other factors in the patient inhalation,
19 did you have specific factors in mind?

20 A. That most obvious is for how
21 long does the patient inhale and how is the
22 aerosol being formed during that time.

23 Q. Is the inspiratory flow of the
24 patient also a factor?

25 A. That's very dependent on

1 MAUREEN DONOVAN, Ph.D.

2 the -- what's being emitted from the nebulizer
3 whether the inspiratory flow add additional
4 effects.

5 Q. In your mind or in your
6 opinion, does the requirement in the claims of
7 a pulsed device require that the pulse equates
8 to one breath?

9 MR. MATHAS: Object to the form.

10 BY THE WITNESS:

11 A. I think you could certainly
12 be -- there are -- would be circumstances
13 where, yes, it could equate to one breath and
14 each breath is a breath that is utilized to
15 inhale the aerosol, and I think there could
16 conceivably be breaths where they were part of
17 the pause.

18 BY MS. ASCARRUNZ:

19 Q. Okay. And could there also
20 conceivably be more than one breath per pulse?

21 MR. MATHAS: Object to the form.

22 BY THE WITNESS:

23 A. Well, if the pulsed ultrasonic
24 nebulizer was configured as a breath-actuated
25 nebulizer, there could be the possibility, but,

1 MAUREEN DONOVAN, Ph.D.

2 again, there's some additional requirements
3 that aren't really clearly specified in the
4 claim so.

5 BY MS. ASCARRUNZ:

6 Q. Okay. If I were to take a
7 sort of standard asthma inhaler and take a puff
8 and then wait a few seconds and then take
9 another puff, is that pulse delivery?

10 A. Under sort of the POSA's
11 understanding of pulse delivery versus multiple
12 dose delivery, yes.

13 Q. Let me turn your attention to
14 paragraphs 126 -- 126 of your '240
15 declaration -- '507 declaration. Thank you.

16 Do you see where you discuss
17 that the primary purpose of using a pulsed
18 nebulizer is to avoid wasting the drug that
19 gets aerosolized while the patient is exhaling?

20 A. I see where it says that, yes.

21 Q. Is this the only possible
22 purpose for using a pulsed nebulizer?

23 A. There are probably others, but
24 this again is one of the key purposes for
25 designing pulsed nebulizers or nebulizers that

1 MAUREEN DONOVAN, Ph.D.

2 pause when the patient is not breathing and the
3 aerosol that's being formed.

4 Q. And how did you determine that
5 this is the primary purpose?

6 A. It's based on my experiences
7 and teaching and understanding of the field of
8 nebulized drug delivery.

9 Q. Let me ask you to look at
10 paragraphs 37 and 38.

11 Do you consider the HaloLite's
12 device to being a pulsed nebulizer?

13 A. It's a breath-actuated or
14 signaled-type nebulizer. I would have to look
15 at the details I think again about the HaloLite
16 to find out whether there's anything else
17 beyond my description in this paragraph to make
18 sure that it doesn't do something else that I
19 wouldn't consider it being a pulsed nebulizer,
20 but it has pause periods and periods that it
21 produces aerosol or at least directs aerosol
22 out the mouthpiece.

23 Q. Unfortunately, we don't have
24 this one printed so let me ask you to get out
25 the two patents again.

1 MAUREEN DONOVAN, Ph.D.

2 Both patents contain a
3 dependent claim limitation, and I will direct
4 you to claim 4 of both patents where the single
5 event dose produces a peak plasma concentration
6 of treprostinil about 10 to 15 minutes after
7 the single event dose, right?

8 A. Yes, that's what they say.

9 Q. What factors impact when the
10 peak -- the time to peak plasma concentration
11 will be?

12 A. The time to peak plasma
13 concentration is highly dependent on the
14 absorption rate of the drug at the site of
15 administration, and the time indicated here is
16 certainly in keeping with the times and the
17 absorption rates known to occur in pulmonary
18 delivery.

19 Q. Are time to peak plasma
20 concentrations similar across all known
21 inhalation therapies, or do they differ? Just
22 leave it at that.

23 A. Well, they would differ
24 between a material being administered as a
25 suspension as compared to a material being

1 MAUREEN DONOVAN, Ph.D.

2 administered as a solution. As long as the
3 material that was undissolved in the suspension
4 actually continues to dissolve and be absorbed
5 in the lungs, one would anticipate a different
6 Tmax than --

7 THE COURT REPORTER: Wait. One
8 would anticipate?

9 BY THE WITNESS:

10 A. A different Tmax, sorry, time
11 to peak plasma concentration than -- I'm sorry,
12 now let me -- so with a suspension formulation,
13 one would anticipate as long as there was
14 continued dissolution and then absorption of
15 the drug that was delivered as the suspension,
16 that that would have a longer Tmax than the
17 same drug administered entirely in solution.

18 BY MS. ASCARRUNZ:

19 Q. So does the solubility of the
20 drug impact the Tmax?

21 A. To be absorbed, the drug has
22 to have been in solution, and the Tmax is
23 affected by the absorption rate. So if there's
24 continued dissolution and continued absorption,
25 that will affect the Tmax because there's a

1 MAUREEN DONOVAN, Ph.D.

2 time lag for all of the drug to go into
3 solution.

4 If the drug is presented in
5 solution, it's there immediately and available
6 for absorption. So the Tmax between those two
7 situations would be anticipated to be different
8 as long, again, as the drug that was
9 administered in the insoluble form actually did
10 continue to dissolve and be absorbed.

11 Q. So that's a, yes, the Tmax is
12 affected by solubility?

13 A. No, it's not. It's affected
14 by how you -- how you present the material that
15 you are intending to be absorbed.

16 Q. Is it affected by drug
17 concentration or volume?

18 A. That depends on the site of
19 administration.

20 Q. So we are talking about
21 inhalation administration.

22 A. Okay. And the Tmax might be
23 affected by the -- more the volume of the
24 aerosol than the volume of the aerosol
25 droplets. It depends on the surface area

1 MAUREEN DONOVAN, Ph.D.

2 that's exposed that's available or that's able
3 to absorb the drug, and the surface area that's
4 exposed is another -- has other factors that
5 influence it. The concentration of the drug.
6 The concentration will affect the Cmax, the
7 peak plasma concentration more than it's going
8 to affect the Tmax.

9 Q. Is the time to peak plasma
10 concentration affected by number of breaths?

11 A. Again, it -- that starts to
12 become very dependent on the characteristics of
13 the material that are being absorbed. So I
14 would have to contemplate a specific material
15 and characteristics and absorption rate to be
16 able to draw some sort of estimate --

17 Q. Okay.

18 A. -- on that.

19 Q. In the context of inhaled
20 treprostnil, does the time to peak plasma
21 concentration depend on the number of breaths?

22 A. Well, I think I am going to
23 have to think about that more. I really -- I
24 don't know that I was -- I know I didn't
25 provide an opinion on alterations in Tmax in my

1 MAUREEN DONOVAN, Ph.D.
2 declaration, and there are just a number of
3 things that need to be held constant in essence
4 for me to be able to answer that question. I'd
5 have to think about what those all are and
6 articulate them. I'd have to take some time to
7 be able to identify that list.

8 Q. Okay. So based on that, I
9 think I know the answer to my question, but I
10 still need to ask it.

11 Sitting here right now without
12 the benefit of that additional analysis that
13 you said would prefer to do, are you able to
14 articulate any factors that would affect the
15 time to peak plasma concentration in the
16 context of inhaled treprostinil?

17 MR. MATHAS: Object to the form.

18 BY THE WITNESS:

19 A. I think I need a more specific
20 question than that especially regarding what
21 inhaled treprostinil are we talking about.

22 BY MS. ASCARRUNZ:

23 Q. What do you mean?

24 A. What concentration of solution
25 are we -- is being inhaled? What particle size

1 MAUREEN DONOVAN, Ph.D.

2 is being inhaled? A number of other things.

3 Q. So would the concentration,
4 particle size, dosage, a number of breaths,
5 timing between breaths, would all of those
6 factors affect the time to peak plasma
7 concentration of inhaled treprostiril?

8 A. Well, there's certainly the
9 chance that they could under the conditions
10 that are being described in the '240 and the
11 '507 patent. If we contain ourselves to that
12 specific -- those specific ranges for
13 treprostiril and the use of the ultrasonic
14 nebulizers and the assumption that those are
15 providing the appropriate particle size for
16 inhalation delivery which is built into all of
17 these claims, that the 10 to 15 minute --
18 that's the timeframe -- 10 to 15 minute
19 timeframe for the Tmax is in keeping with the
20 expectation of a POSA for the system that's
21 described by the claims in the '507 and '240
22 patents.

23 Q. Okay. Do you agree with me
24 that certain of the dependent claims in the
25 patents relate to the micrograms of

1 MAUREEN DONOVAN, Ph.D.

2 treprostiniil per breath?

3 A. Yes. For example, claim 6 in
4 the '240 as a dependent claim describes at
5 least 5 micrograms of treprostiniil or its
6 pharmaceutically acceptable salt.

7 Q. Does -- in the context of the
8 administration of treprostiniil under the
9 claims, does the droplet size affect what the
10 micrograms per breath would be, or can the
11 droplet size affect what the micrograms per
12 breath would be?

13 A. Only indirectly. The number
14 of micrograms per breath is determined by the
15 volume of aerosol emitted, and the actual
16 deposition into the respiratory tract is
17 certainly dependent on particle size. So
18 indirectly, yes, but the direct delivery from
19 the device is a function of the concentration
20 of the fluid that's being aerosolized and the
21 volume of -- the total volume of aerosol formed
22 able to be inhaled.

23 Q. Does the microgram per breath
24 inhaled by the human also depend on that
25 person's breathing capacity?

1 MAUREEN DONOVAN, Ph.D.

2 A. Depending on how the aerosol
3 is -- how it forms, what its characteristics
4 are, there certainly are characteristics of the
5 aerosol that will be dependent on patient
6 inhalation conditions. There are also
7 characteristics of aerosols where the patient
8 conditions are certainly significantly blunted.
9 That they are not significantly dependent or
10 that they don't offer -- or they don't result
11 in a significant difference in the delivery.
12 So it's again a more of a slightly more
13 complicated interface between the aerosol being
14 produced and the user.

15 Q. We talked about the two
16 patients in Voswinckel that were treated for a
17 longer term.

18 Are those two patients part of
19 the 17, or is it 17 plus two patients that were
20 treated in total in that study?

21 A. Based on the notation that the
22 two patients who received the compassionate use
23 treatment received it after the acute test,
24 they would have been part of the 17 patients
25 that underwent the acute test.

1 MAUREEN DONOVAN, Ph.D.

2 Q. Okay. Let me ask you to turn
3 to paragraph 126 of the '240 declaration.

4 MR. MATHAS: Veronica, when you get
5 a chance, maybe we can take another or an
6 afternoon break.

7 MS. ASCARRUNZ: Yeah, this is a
8 great time actually. Are you ready to take a
9 break?

10 THE WITNESS: Yes. That would be
11 appreciate, thank you.

12 THE VIDEOGRAPHER: Going off the
13 record. The time is 2:46 p.m.

14 (WHEREUPON, a recess was had at
15 2:46 p.m. until 3:05 p.m.)

16 THE VIDEOGRAPHER: Going on the
17 record. This marks the beginning of media
18 number 4. The time is now 3:05 p.m.

19 BY MS. ASCARRUNZ:

20 Q. Dr. Donovan, can you give me
21 an example of an inhalation device that does
22 not use pulsed delivery, and I should clarify
23 within the meaning of the claims?

24 A. So ultrasonic nebulizers that
25 couldn't be configured for pulsed delivery.

1 MAUREEN DONOVAN, Ph.D.

2 I'm -- I'm sure there is a nebulizer in a
3 system. I would suspect that in particular if
4 the formulation viscosity was somewhat higher
5 than -- than water, the traditional
6 formulations that are currently used, that the
7 response time for the nebulizer might be such
8 that it really wouldn't be effective in pulsed
9 delivery. So that it would have to have a
10 different sort of delivery time relationship,
11 but, you know, it's not something I have spent
12 any time thinking about.

13 Q. Okay. Fair enough.

14 In the course of our
15 discussion today and in the course of your
16 preparation for today, did you identify any
17 portions of your declaration that are
18 incorrect?

19 A. I continue to find typos that
20 make me wonder why I hadn't seen them before
21 or, you know, a word choice or something, but
22 there's nothing of substance in my declarations
23 that I have found that I no longer agree with
24 or think need to be communicated in a different
25 way.

1 MAUREEN DONOVAN, Ph.D.

2 MS. ASCARRUNZ: Okay. I have no
3 further questions at this time.

4 EXAMINATION

5 BY MR. MATHAS:

6 Q. Just a couple questions.

7 Dr. Donovan, early in your
8 deposition, counsel for the patent owner asked
9 you some questions about how you would go about
10 researching a particular -- a scientific area
11 of interest.

12 Do you recall those?

13 A. Yes.

14 Q. And you mentioned using some
15 online databases and running searches.

16 Do you recall that?

17 A. Yes.

18 Q. How, if at all, would you have
19 used information if you knew a particular
20 researcher or group of researchers was
21 interested in the topic of interest?

22 MS. ASCARRUNZ: Objection to form.

23 BY THE WITNESS:

24 A. Okay. You know, it's sort of
25 the same process. Most of the databases that I

1 MAUREEN DONOVAN, Ph.D.
2 mentioned so Web of Science, PubMed,
3 International Pharmaceutical Abstracts, and
4 chem abstracts for lack of a better phrase for
5 what they are called, offers you the
6 opportunity to search the authors. So I can --

7 THE COURT REPORTER: I'm sorry.

8 BY THE WITNESS:

9 A. I'm sorry. Offers the
10 opportunity to search authors. So if there's a
11 particular research group that I am interested
12 in, I will just search based on the author, and
13 that's the advantage of using Web of Science
14 even is it gives -- it both gives the
15 publications the author is named in, and it
16 also gives easy access to all the people who
17 have cited those same publications.

18 So you can expand your family
19 of people of interest pretty rapidly. So just
20 searching based on a particular group that I
21 was interested in, knew that they were doing
22 work is just as easy as doing a topic search.

23 BY MR. MATHAS:

24 Q. In your experience,
25 Dr. Donovan, why do researchers present their

1 MAUREEN DONOVAN, Ph.D.

2 research at a conference?

3 A. They both want to demonstrate
4 the things that they are doing that are -- and
5 usually they're novel and hope people are
6 interested in them and most of the time no
7 people are interested in them because they are
8 choosing topics that they know are pertinent to
9 the particular group that they are presenting
10 in front of, and they want to be able to
11 describe the work they are doing before perhaps
12 they even have enough data to completely write
13 a manuscript and have that go through review
14 and be published and so forth.

15 Now it's not quite as bad.
16 Back in the day, manuscript writing to actual
17 hard copy publication time might be a year and
18 a half or longer when you got into the queue
19 for particular journals. Now with electronic
20 access that becomes less of an issue, but it
21 became a -- that's why you present so that
22 people understood what you were doing in
23 realtime almost versus, you know, two years
24 previous. It also allows you to find
25 collaborators, people who are interested in the

1 MAUREEN DONOVAN, Ph.D.

2 same things, lots of other reasons why.

3 Q. And in your experience why,
4 Dr. Donovan, are abstracts of presentations
5 published?

6 A. Because they describe bodies
7 of knowledge and bodies of work that people
8 have been accomplishing. They are just not in
9 the format for complete publication. When
10 things are presented at meetings, there's a
11 whole group of interested scientists who don't
12 attend that meeting.

13 So you have the ability then
14 as -- you know, with a published abstract to
15 also inform others who weren't physically
16 present at a meeting what took part, what was
17 the latest information being presented, who is
18 doing things in a similar area that people look
19 at but just can't afford the time or the money
20 to attend every meeting that something might be
21 presented at.

22 MR. MATHAS: Thank you, Doctor. I
23 have no further questions?

24 THE WITNESS: Okay. Thanks.

25 MS. ASCARRUNZ: No questions from

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

MAUREEN DONOVAN, Ph.D.

me. Thank you for your time.

THE VIDEOGRAPHER: Going off the record. The time is 3:12 p.m.

(WHEREUPON, the deposition was concluded at 3:12 p.m.)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

STATE OF _____)
) : ss
COUNTY OF _____)

I, MAUREEN DONOVAN, Ph.D., the
witness herein, having read the foregoing
testimony of the pages of this deposition,
do hereby certify it to be a true and
correct transcript, subject to the
corrections, if any, shown on the attached
page.

MAUREEN DONOVAN, Ph.D.

Sworn and subscribed to before me,
this _____ day of _____, 2018.

Notary Public

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

CERTIFICATE
OF
CERTIFIED SHORTHAND REPORTER

I, ANDREA L. KIM, a State of Illinois
Licensed Certified Shorthand Reporter, License
number 84-3722, do hereby certify:

That previous to the
commencement of the examination of the
aforesaid witness, the witness was duly sworn
or affirmed to testify the whole truth
concerning the matters herein;

That the foregoing deposition
transcript was reported stenographically by me,
was thereafter reduced to typewriting under my
personal direction and constitutes a true and
accurate record of the testimony given and the
proceedings had at the aforesaid deposition;

That the said deposition was
taken before me at the time and place
specified;

That I am not a relative or
employee or attorney or counsel for any of the
parties herein, nor a relative or employee of

1
2 such attorney or counsel for any of the parties
3
4 hereto, nor am I interested directly or
5 indirectly in the outcome of this action.
6

7 IN WITNESS WHEREOF, I do
8 hereunto set my hand and affix my seal of
9 office at Chicago, Illinois, this 5th day of
10 April, 2018.
11

12 

13 ANDREA L. KIM, CSR

14 License No. 84-3722.
15
16
17
18
19
20
21
22
23
24
25

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

INSTRUCTIONS TO WITNESS

Please read your deposition over carefully and make any necessary corrections. You should state the reason in the appropriate space on the errata sheet for any corrections that are made.

After doing so, please sign the errata sheet and date it.

You are signing same subject to the changes you have noted on the errata sheet, which will be attached to your deposition.

It is imperative that you return the original errata sheet to the deposing attorney within thirty (30) days of receipt of the deposition transcript by you. If you fail to do so, the deposition transcript may be deemed to be accurate and may be used in court.

E R R A T A

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

I wish to make the following changes,
for the following reasons:

PAGE LINE

____ CHANGE: _____

REASON: _____

____ CHANGE: _____

REASON: _____

____ CHANGE: _____

REASON: _____

____ CHANGE: _____

REASON: _____

____ CHANGE: _____

REASON: _____

____ CHANGE: _____

REASON: _____

WITNESS' SIGNATURE

DATE

&	10:55 54:10,13	2005 49:14,17	3
& 2:3,10,17 5:14 5:24 6:3	11 6:24	51:10,12,21 64:7	3 106:3
0	110 76:2	81:12,14,24 82:4	30 93:19 166:14
01621 13:17	111 32:17	82:10,19 83:20	3000 2:18
01622 13:16	112 31:17	2006 23:24 24:5	31 62:16
1	121 78:19	26:12 27:24 33:4	312-558-8329 2:6
1 5:4 15:9,15,16	125 112:6 114:6	42:4,9 43:12	32 88:12
15:17 72:17,22	127:25	2017 49:25	35 1:18 2:4 5:8
73:7,9 107:13,21	126 146:14,14	2017-01621 1:6	37 147:10
107:23 108:21	156:3	9:16,19	38 147:10
109:5,10 137:15	12:17 105:22,24	2017-01622 1:7	3:05 156:15,18
137:16 138:5	13 4:11,12	8:19 9:3	3:12 162:4,6
10 148:6 153:17	136 84:14,15	2017-1621 5:20	4
153:18	15 33:4 74:18	2018 1:20 5:10	4 41:16 148:4
100 59:10	88:22 89:5,16	49:24 50:23	156:18
1001 4:11,12	90:2,17,25 148:6	163:21 165:10	4/4/18 8:23 9:12
13:10,10,15,17	153:17,18	202-672-5569 2:20	13:11 46:5,16
14:2,7,19 16:19	158 4:6	202-973-8812 2:13	47:14 48:5 86:16
1002 4:13,14 8:18	16 88:12	207 53:23,25	46 4:15,16
8:22 9:11,15	1621 46:25 47:4	54:17 57:3,11	47 4:17
1003 4:15 46:4,8	1622 5:20	209 58:9	48 4:18 88:13
1004 4:16 46:15	17 73:22 74:6,7,9	21 105:17	4800 1:18
46:19 47:3	74:16,18,22 75:4	210 130:8	4th 1:19 5:10
1005 4:17 47:13	75:8,14 77:22	213 134:13,14	5
47:17	85:23 155:19,19	240 10:11,18,22	5 154:5
1012 4:18 48:4,7	155:24	11:3 15:14 33:3	507 10:10,14,21
104 79:2	1700 2:11	35:25 36:24 53:24	11:4 15:8,13
1046 4:19 86:15	180 90:18 91:2	54:23 55:7 62:16	35:21 63:19
86:19 89:4 90:9	1:23 105:24 106:3	62:18,21 63:15	108:20 111:16,22
91:22 121:19,21	2	73:19 111:18,21	124:16 126:11
1047 121:10,13	2 15:9,15,17 37:12	112:7 123:18,21	136:10 137:16
105 9:7,7 95:10,11	54:13	124:17 126:11	146:15 153:11,21
108 72:15,20 73:6	20 93:19 94:4	130:8 134:13	54284 1:22
73:8	20006-3817 2:12	136:10 137:11,12	56 64:4
109 73:21	20007 2:19	137:16 138:6	5th 165:9
10:31 45:18	2000s 42:22	146:14 153:10,21	6
10:32 45:22	2004 21:15,16	154:4 156:3	6 4:5 15:18 154:3
10:43 54:8,10	22:15,17 23:13	26 70:25 71:5	600 2:18 74:2 77:7
	49:13,16 70:5,8	2:46 156:13,15	79:7
	70:17 71:2,5,13		

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

<p>60601 2:5 64 88:13 7 71 62:20 72 32:24,25 44:10 73 36:23 41:14 74 43:7,10 44:10 8 8 4:13 80 69:25 84 56:25 84-3722 1:18 3:23 164:8 165:14 85 81:10 86 4:19 9 9 4:14 9,339,507 9:4 9,358,240 9:20 90 88:23 90:19 91:3 103:10 91 9:23,23 951 120:20 9:37 1:20 9:41 5:10 a a.d. 1:20 a.m. 1:20 5:10 45:18,22 54:8,10 54:10,13 abandoned 33:17 abbreviated 117:12,14 119:7 abilities 61:16 ability 41:5 60:14 69:14 88:23 95:23 96:25 101:9 116:22 118:2 134:7 136:20</p>	<p>161:13 able 11:19 28:23 28:24 30:15 51:13 51:21 53:3 58:19 59:10 61:14 96:21 97:4,15 100:24 101:24 102:3 128:15,18 135:16 138:7 151:2,16 152:4,7,13 154:22 160:10 absence 135:16 absolute 88:24 absolutely 49:17 absorb 151:3 absorbed 149:4,21 150:10,15 151:13 absorption 148:14 148:17 149:14,23 149:24 150:6 151:15 abstract 25:4 28:16 29:11,17,25 48:24 49:4,18 61:24 62:4 64:18 65:4,10,12,22 66:25 69:24 70:14 70:22 75:7 77:13 77:16,17 84:24 85:4,6,11 86:12 87:11,21 88:10 89:2,18 90:16,21 91:19 92:17 94:19 113:11,12,13 114:4 117:11,11 117:15 118:6 119:7 120:8 121:23 122:19,22 124:4,13,20,24 125:13 127:11,14 139:10 161:14</p>	<p>abstracts 21:2 23:19 24:10,11,14 24:15,16,17,22 25:4,7,16 28:12 28:13,18,25 29:4 29:9 30:21 72:3,4 113:21 159:3,4 161:4 academic 61:6 academics 61:8 accept 101:8 acceptable 138:8 154:6 acceptances 43:23 accepted 28:17 access 22:8 26:4 28:6,24 34:10 50:10 51:2 53:4 72:10 159:16 160:20 accessible 29:3 48:20 49:9 50:18 accomplish 98:18 100:25 102:23 accomplished 67:8 123:8,9 accomplishing 113:24 161:8 accuracy 96:9 100:14 accurate 44:19 100:21 118:10 164:18 166:16 accurately 35:13 101:9 achieve 99:18 121:2 123:3 achieved 128:7 129:7 achieving 62:8</p>	<p>acknowledges 100:16 acoustic 106:17,23 106:24 107:21,24 109:20 111:24 116:6 acoustical 106:13 106:19 107:11 109:3,8,18 action 16:12 165:5 activities 114:25 123:10 activity 96:2 98:19 actual 23:8 40:5 49:15 53:10 65:11 66:4 67:22 125:16 154:15 160:16 actuated 143:21 143:25 144:5,11 145:24 147:13 acute 67:18,19 75:13 76:12 77:4 77:22 78:12 118:4 128:19 155:23,25 add 145:3 added 32:16 addition 62:6 123:10 128:18 additional 10:15 10:22,25 65:5 75:2,11 102:11 112:24 127:13,13 127:16 145:3 146:2 152:12 address 100:19 126:20 addressed 100:20 addresses 10:21 adequate 13:23 adhere 128:25</p>
--	--	--	---

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

adherence 123:5 126:16 administer 138:25 administered 80:8 96:17 148:24 149:2,17 150:9 administering 139:21 administration 37:16 79:6 99:19 133:5,17 134:2 139:5 148:15 150:19,21 154:8 administrations 134:7 admitted 83:20 advantage 117:21 122:8 159:13 aerosol 80:21,23 80:25 81:3,5 91:25 92:11,14 95:23 96:12 97:12 97:16,19,25,25 98:8 99:2 101:22 103:12,19,21 104:4,11,14,15,25 105:4 109:22 115:5 140:11 141:3,8,9,10,21 141:23,24 142:5,6 142:15,16,18,18 142:19,19 143:4,5 143:7,17,25 144:2 144:22 145:15 147:3,21,21 150:24,24 154:15 154:21 155:2,5,13 aerosolization 98:18 aerosolized 97:24 139:23 146:19	154:20 aerosolizes 102:21 107:14 aerosolizing 140:23 aerosols 104:2 137:20 138:2 155:7 affect 149:25 151:6,8 152:14 153:6 154:9,11 affirmed 164:12 affix 165:8 afford 161:19 aforesaid 164:11 164:19 afternoon 156:6 agent 68:24 69:15 ago 129:10 agree 12:14,16 28:13,15 32:7 44:2 78:19 92:23 92:25 100:21 107:9 108:8 109:4 109:9 133:3,15 134:17 137:12 153:23 157:23 agreements 24:21 25:11 ahead 13:6 air 95:6 102:20 106:9 airways 100:2 allow 69:15 133:25 134:10 allowed 112:25 allows 97:10 111:25 134:9 160:24 alterations 129:3 151:25	alternatives 103:2 american 23:21 64:17 122:22 amount 78:21 93:20 95:5,6 96:4 97:12,15,23 99:18 101:5,6,9,14 123:2 138:7,9,18 139:4,22 140:23 141:7 144:12 amounts 99:14,17 analog 38:10 analysis 35:10 152:12 anatomy 41:5 andrea 1:16 3:22 164:6 165:13 annually 41:22 answer 7:16,23 8:10 16:23 26:21 52:10,13 58:20 118:24,25 125:25 152:4,9 answered 49:6 120:4 answering 73:3 125:11 answers 7:14 8:15 anticipate 77:13 83:13 110:10 149:5,8,13 anticipated 150:7 anyway 99:16 apart 10:24 appeal 1:3 63:10 appear 24:22 50:24 72:7 appeared 2:9,25 49:14 appears 9:5,21 36:4 40:21 66:6	67:24 69:10 84:16 105:13 application 35:4 120:21 applies 108:3 appreciate 33:22 52:21 86:8 94:25 156:11 approach 30:12 61:5 approaching 49:19 93:19 appropriate 30:24 34:10 36:21 153:15 166:5 appropriately 116:15 approval 19:12,17 58:23 132:22 approved 19:11 19:17 58:17,22 59:4,16 68:22 69:16 approximately 6:23 april 1:20 5:9 82:17 165:10 area 21:17 27:6,10 30:19 39:18 41:18 41:24 42:11 53:3 60:17 71:17 91:15 98:19 150:25 151:3 158:10 161:18 areas 56:9 60:12 96:14 arguments 134:17 135:5,15,21,24 arms 69:13 arrive 114:20
---	--	---	---

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

<p>arrived 71:14 art 24:4 26:10 27:11,23 31:8,11 32:23 33:5 34:18 37:6,13,15,23,24 38:25 39:2,16,20 45:2 48:21 49:10 50:19 51:25 53:12 55:9,15,24 56:4,8 57:13,21,24 62:23 63:7 73:16 83:11 83:14,14 98:3 109:13,25 110:2,4 112:18 113:22 114:19 115:13,20 119:5 143:21 arterials 41:3 artery 75:17 article 22:23 82:23 articles 20:24 23:8 73:19 articulate 11:21 29:23 131:8 152:6 152:14 articulated 31:4 ascarrunz 2:14 4:5 5:22,23 6:14 8:24 9:13 11:14 12:13,19 13:12 27:19 44:5 46:6 46:17 47:5,8,15 48:6 53:5 54:14 56:15,24 60:19 61:18 65:13 78:6 84:2 86:17 89:7 89:23 90:23 91:21 95:7 106:4 108:2 108:17 110:23 111:14 114:2 115:16 116:24</p>	<p>118:13,20 119:10 120:13 121:6,20 126:2,23 131:6 133:12 136:21 137:5 140:2,18 141:13 142:12 143:2,19 144:16 145:18 146:5 149:18 152:22 156:7,19 158:2,22 161:25 asked 31:19 117:3 120:4 122:2 158:8 asking 7:15 52:6 119:11,25 124:2 125:11 aspect 123:4 aspects 26:23 56:6 105:11 129:22 asserted 33:3 62:21 assess 40:13 53:7 66:23 assessable 82:6 assessment 33:25 34:7 81:19 associated 25:14 25:18 79:20 association 25:15 25:19 64:18 122:22 association's 25:11 26:5 associations 24:20 assume 7:24 93:15 98:24 assuming 54:20 assumption 48:21 77:9 132:25 153:14</p>	<p>asthma 146:7 atmosphere 96:13 attached 163:12 166:11 attempt 59:13 attempting 36:14 attend 28:23 41:21 161:12,20 attendees 71:22 72:6,10 attention 62:19 72:15 78:19 103:10 146:13 attorney 164:24 165:2 166:13 attorneys 5:11 attributed 58:12 96:12 attributes 115:6,7 133:4,16 audible 98:11 author 65:6 91:16 159:12,15 author's 125:14 authors 68:11 69:5 124:7 125:3 126:5 127:12 159:6,10 availability 83:7 97:6,18 available 49:2,13 50:7,8,11 51:9 52:18,22 56:4 57:24 70:7,16,25 71:4 72:6 80:19 81:13,23,24,25,25 82:5,7,23 95:24 97:13,17 98:6 99:7 115:8 116:12 133:2 150:5 151:2</p>	<p>avenues 21:17 avoid 146:18 aware 8:13 27:15 38:4,9 41:20 43:14,19 44:14 59:15 60:10 61:19 62:11,13 63:9,12 80:3 81:24 83:19 83:24 84:6 113:15 114:25 123:12,15 126:19 131:18 132:15,21 136:5 awareness 84:10</p> <hr/> <p style="text-align: center;">b</p> <hr/> <p>b 2:21 back 21:14,24 26:11 28:12 77:4 82:11 93:7 96:19 107:2 137:6 140:13,16 142:17 160:16 background 12:14 38:19 131:23 bad 160:15 base 56:2 80:17 based 29:12 36:4 44:17 55:22 60:17 76:6,9 79:23 80:10,18 91:9,16 97:14 102:2,6 106:22 107:12 116:11 129:4 147:6 152:8 155:21 159:12,20 basis 27:5 69:15 85:9 87:23 92:12 bear 9:6,22 beginning 5:3 54:12 106:2 156:17</p>
--	--	--	--

behalf 2:9,25 5:14 20:7,11,16	bracket 87:16	built 153:16	cause 30:19 57:17
belief 52:20	bracketed 87:15	bullet 63:6	cd 72:5,12
believe 10:12	brand 20:11 59:11	c	cease 143:4
32:23 34:13 36:15	break 8:5,11 54:5	call 8:6 99:16	ceases 107:6
43:9 44:18 51:11	54:16 93:16,21,22	106:23	cell 41:12
51:20 52:25 66:20	93:22 105:19	called 1:12 6:10	certain 8:20 9:9
72:11 76:19 82:13	110:21 156:6,9	23:18 159:5	13:8 26:14 46:2
114:9 119:16	breaking 105:18	canada 20:12	46:13 47:11 48:2
127:18 135:17	breaks 8:4	capabilities 35:13	59:19 60:3 62:23
139:20 142:22	breath 73:23	116:5	63:6 86:13 89:21
benefit 40:10,16	74:17,19,23 75:5	capable 116:20	153:24
152:12	76:21 80:12 102:5	121:3 137:19,25	certainly 21:3,23
benefits 58:10	111:25 141:15	139:21 144:11	22:2 23:16 34:12
bennett 70:10,17	143:21,25 144:5	capacity 154:25	38:4,16,23 39:15
70:20 83:19 84:4	144:10 145:8,13	capillaries 41:3	40:3,10,12 42:17
bennett's 81:18,21	145:14,14,20,24	caption 5:17,18	48:25 49:13 56:5
82:14	147:13 154:2,10	cardiovascular	66:14 67:14 71:13
best 69:12 109:14	154:12,14,23	64:8	72:7 82:12,18
115:12,19 118:8	breathes 80:6	care 69:2 118:4	83:16 91:17 98:20
better 25:15 31:4	breathing 79:22	career 20:20	100:15 101:3
68:19 123:14	144:3 147:2	carefully 166:3	102:5,18 105:14
159:4	154:25	carl 35:20,23	113:15,22 115:3
beyond 124:11	breaths 75:10,15	carry 109:24	118:6 122:25
136:20 147:17	76:17 77:7,11	case 8:19 9:2,18	123:10 126:10
bit 8:4 54:3 81:7	79:4,9,13,17	16:17 18:4,20,24	127:22 131:7
93:13	122:23 126:25	31:6,11,12 33:2,8	132:20 143:11
block 60:4	127:5,21 138:24	33:24 36:6,7	145:11 148:16
blocked 59:20	139:3 141:20,20	43:15 44:13 79:18	153:8 154:17
bloodstream 41:6	145:16 151:10,21	96:16 99:15	155:4,8
41:9	153:4,5	111:23 112:2	certificate 164:2
blunted 155:8	brief 45:10	115:14 130:19	certified 1:17
board 1:3 7:11	briefly 130:17	132:16,20 136:7	164:4,7
63:10 123:16	bringing 42:16,19	cases 20:3,5,14	certify 163:10
bodies 161:6,7	broad 40:25 103:7	29:13 53:15	164:8
body 30:21 40:9	broaden 56:10	casual 38:18	cetera 11:2
119:8	broader 99:24	catalogued 82:18	chamber 97:3
bold 14:13	100:6	catheretization	109:23
bolus 99:9 101:18	brought 103:21	69:7	chance 70:3 153:9
bottom 14:7,12	bs 33:18	catheter 75:17	156:5
	building 16:11	catheterized 77:22	change 30:11,11
	34:19		42:6,19 44:17

54:3,24 55:12 93:13 120:9 123:9 167:9,11,13,15,17 167:19 changed 55:18 113:14 117:16 changes 23:25 33:23 103:3 117:20 122:7,16 166:9 167:5 changing 42:8,24 characteristics 38:16 117:22 118:8 122:8 134:2 134:11 151:12,15 155:3,4,7 characterization 119:19 characterize 10:17 12:5 chaudry 10:9,16 45:6 46:21,24 50:17,22 63:22 check 10:13 85:3 chem 159:4 chemical 23:21 38:16 chemistry 38:20 chicago 1:19 2:5 5:9 165:9 choice 157:21 choose 27:9 chooses 98:13 choosing 160:8 chose 88:18 chronically 77:24 circulation 52:24 70:6,14 85:7 86:12 113:11,13 117:11 118:5 120:7	circumstances 145:12 citation 48:24 49:4 65:19 85:5 86:2 87:9,9 90:7 90:16 91:4 citations 29:14 91:8 cite 21:6 28:25 29:4 70:8 73:14 134:21,24 cited 23:6 64:7,23 65:12 66:5 84:21 85:13 86:21 87:18 87:24 91:19 159:17 cites 86:5 87:2 90:14 citing 65:12 87:4 91:10 civil 1:14 claim 15:9,9,16,17 15:17,17,24 16:3 17:16,22 19:7 33:4 34:22 72:17 72:21 73:7,9 106:12 107:13,21 107:23 108:21 109:5,10,11 112:3 131:24 132:5 137:15,15 138:5 138:13,18,21,23 139:6 146:4 148:3 148:4 154:3,4 claimed 114:20 claims 15:6,10,13 15:15,16,21 32:10 33:3 34:2 57:14 62:21 63:3,15,20 100:4 107:10,23 108:6,10,21 109:5	110:7,17 111:4 135:23 136:6,9,11 136:13,17 137:3 137:13,22 139:9 139:12,17 140:7 140:21 141:15,17 142:2,7,14 143:8 144:7 145:6 153:17,21,24 154:9 156:23 clarification 14:11 46:24 121:5 clarify 93:6 156:22 clarity 47:3 122:14 clear 12:23 68:23 73:18 75:3 80:7,9 82:15 113:20 124:20 125:16 127:15 clearly 33:16 34:18 124:19 146:3 clinical 18:16 66:17,23 67:11 68:16,17 69:17 clinically 68:7 132:10 cmax 151:6 collaborator 30:14,16 collaborators 160:25 collection 21:21 51:4 71:19 combination 33:11 59:17 128:4 128:4 combinations 19:16 62:23 63:2	63:6 combine 112:8,16 114:6,12 115:23 119:5,14 123:23 129:5 come 90:20 93:7 107:2 124:15,15 comes 107:4 comfort 93:25 comfortable 28:2 94:3 commencement 164:10 comment 136:20 commercial 42:17 58:6,7 61:10 commercialize 60:11,14,21 commercially 132:18 common 58:24 communicate 130:10 131:10,12 communicated 157:24 company 20:7,17 compare 117:14 compared 86:11 133:7,18 148:25 comparing 113:11 113:21 compassionate 67:5 68:9,13 69:13,19,23 74:12 75:12 77:2,20 78:9,15 128:21 155:22 compatibilities 38:21 complete 8:14 34:15 161:9
--	---	--	---

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

<p>completely 21:22 160:12</p> <p>complicated 155:13</p> <p>component 15:5 116:7</p> <p>compounds 38:11 38:20</p> <p>compressed 95:6 103:22 104:10 106:9</p> <p>compressor 95:6 106:7 107:6</p> <p>comprising 74:2 107:20 108:22 109:3,7 111:24</p> <p>conceivably 143:17 145:16,20</p> <p>conceived 34:2,8 34:24</p> <p>concentration 89:19 134:9 148:5 148:10,13 149:11 150:17 151:5,6,7 151:10,21 152:15 152:24 153:3,7 154:19</p> <p>concentrations 88:12 148:20</p> <p>conception 34:14 35:6</p> <p>concerning 164:13</p> <p>conclude 85:10 87:23</p> <p>concluded 162:6</p> <p>conclusion 76:7</p> <p>conditions 67:2,15 87:12 88:2,8 101:25 106:25 153:9 155:6,8</p>	<p>conduct 69:6</p> <p>conducted 67:16 86:2 91:13 124:5 124:25</p> <p>conference 71:22 71:23 160:2</p> <p>confident 113:24</p> <p>configure 143:14</p> <p>configured 145:24 156:25</p> <p>confirm 33:19</p> <p>confused 142:10</p> <p>connection 9:3,19 10:10 14:22,23 16:12 17:2</p> <p>consider 37:8,11 38:6 39:4 41:15 56:17 106:18 114:11 143:12 147:11,19</p> <p>consideration 38:19 57:23 124:22 132:16 134:16 135:5,15</p> <p>considerations 54:22 55:4,6,17 56:6 114:10 119:17,23 135:21</p> <p>considered 37:5 38:12 99:17,20 141:11 142:13 144:14</p> <p>considering 39:12</p> <p>consistent 11:5,13 90:9</p> <p>constant 68:4 91:24 139:13 140:4 152:3</p> <p>constitutes 164:17</p> <p>constraints 61:12</p>	<p>consult 23:14,16 23:17,19</p> <p>contact 41:7</p> <p>contacting 41:8</p> <p>contain 101:22 148:2 153:11</p> <p>containing 10:17 59:22 60:6,24 70:15 97:12 102:21 109:22</p> <p>contains 10:15,22 65:16</p> <p>contemplate 120:12 151:14</p> <p>contemporary 53:11</p> <p>context 11:25 12:14 32:17,19 42:2 137:8,22 151:19 152:16 154:7</p> <p>continuations 33:17</p> <p>continue 30:20 32:3 52:12 86:10 139:23 150:10 157:19</p> <p>continued 68:4 149:14,24,24</p> <p>continues 149:4</p> <p>continuing 69:12</p> <p>continuous 91:24 92:11,12,21 117:17</p> <p>controlled 77:18</p> <p>conversations 84:3</p> <p>conveyed 29:18</p> <p>coordination 62:9</p> <p>copy 8:25 50:7 51:13,22 71:8</p>	<p>72:7 81:23 83:2,3 160:17</p> <p>corp 1:7 5:21</p> <p>corporation 5:6</p> <p>correct 6:21 10:11 10:12,13 14:8,19 14:20 15:3,7 16:14,19,20,23 17:14,17,20,24 18:5,17,18,21 19:2,5,8,13,14,18 19:19,21,22 20:3 20:8,17,21 21:6 24:10 28:14 31:8 31:14 35:11 36:3 37:6 44:11,23 50:5 52:2,8 53:8 56:18 59:22 61:22 63:7,8,17,22 64:2 68:10 72:17,22 73:7,11,12,14 74:8 75:6,23 76:8 76:13 78:22 79:4 83:8 84:22 85:2 86:6 89:5 90:3 91:4,25 92:4 93:10 94:10,14 99:22 100:11 104:21 106:7,14 107:6 108:4 110:3 123:20,24 125:5,8 129:9 130:6 131:9 132:3,4,9,18,23 133:8 134:23 136:8,14,24 138:2 163:11</p> <p>corrections 163:12 166:4,6</p> <p>correctly 112:23 114:13 116:23 118:3</p>
--	--	---	--

corroborate 30:9	49:22,24	134:13 146:15,15	156:22,25 157:9
counsel 6:2 33:10 33:19 48:12,15,17 48:22 158:8 164:24 165:2	databases 22:6,18 23:13,15 27:13,20 50:24 57:16 58:3 83:15 158:15,25	152:2 156:3 157:17	157:10 demonstrate 110:14 124:9 128:18 160:3
count 96:25	date 21:22 33:2,9 33:14,20,21 34:7 34:14,15 40:3 70:24 82:11 83:17 83:21 126:10 166:8 167:23	declarations 10:2 10:5 11:20 12:6 45:11 53:14 59:24 83:8 129:12 131:2 131:17 157:22	demonstrated 125:20 demonstrates 110:25 123:11
county 163:4	dates 33:14 34:12 35:10 50:25 82:22 83:16 91:9	deemed 166:16	demonstrating 57:13 109:22
couple 22:4 71:11 100:5 158:6	day 1:19 73:24 74:11,18,23 75:6 75:13 76:21 77:3 77:11,19 160:16 163:21 165:9	define 35:3 43:2 77:5	depend 51:17 151:21 154:24
course 20:19 130:18 157:14,15	days 166:14	defined 24:5 27:23 32:11,22 44:10 95:5 108:15	depended 51:17
court 5:7,18 6:5 7:13 9:14 13:13 16:12 18:19,24 36:7 43:22 56:16 107:16 149:7 159:7 166:16	dc 2:12	definitely 81:6	dependency 108:6 109:6
courtroom 7:11	deal 26:16 38:3	definition 43:5,21 43:23 44:19,20 93:3 142:23	dependent 15:10 15:11,13,17 27:13 107:23 144:25 148:3,13 151:12 153:24 154:4,17 155:5,9
courts 1:15	december 70:8,16 71:12	definitions 44:15	depending 12:25 139:2 155:2
cover 70:24 111:19	decide 30:12 60:16	degree 12:9	depends 22:19 93:18 99:3 144:10 150:18,25
covered 60:12	decision 123:17	deliver 94:13,20 95:14 120:23 138:7 140:16,17 144:12	deposed 6:20,25 16:10 84:9
credible 130:21 131:9,14	declaration 9:2,6 9:18 10:15,17,19 10:20 11:4,4 14:3 31:18 32:10,24 36:24 43:2 45:2 50:5 51:23 52:7,8 52:19 53:6,13,24 62:2,17 70:10 72:24,25 83:12 93:9 94:10 103:11 112:7 129:15,18 129:24 130:5,6,8 130:10,16,20 131:3,8,11,13	delivered 101:14 126:25 138:10 149:15	deposing 166:13
cross 22:21		delivering 39:17 137:20,25	deposition 1:11 5:4,8 8:21 9:10 13:6,9 16:22 17:2 17:6,9 20:6,10,15 46:3,14 47:12 48:3 83:21 84:7 84:12 86:14 154:16 158:8 162:5 163:9 164:14,19,20 166:3,11,14,15
csr 1:17 3:23 165:13		delivers 42:7 140:14 144:2	
current 27:2 69:16		delivery 37:17,18 37:20,24 41:13,20 55:25 79:3 80:22 95:19 100:18 101:2 115:2 138:11,16 141:12 142:23 146:9,11 146:12 147:8 148:18 153:16 154:18 155:11	
currently 21:12 22:16 27:18 39:19 62:14 157:6			
d			
d 4:1,9			
d.c. 2:19 5:25 6:3			
daily 75:22			
dark 14:12			
data 29:17,18,25 160:12			
database 23:17,20 23:22 49:12,15,20			

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

<p>depositions 1:16 derive 101:11 describe 11:12 35:3 67:2 83:9 84:16 85:22,24 87:11 95:3 97:4 98:3 101:21 104:10 105:2,6 160:11 161:6 described 23:25 43:10 45:10 53:11 65:10 76:15 78:12 78:14 87:12,22 89:14 92:20 102:9 104:16,16,22 105:16 107:7 116:6,10 118:5 120:17,20 125:13 153:10,21 describes 66:22 79:5 87:25 93:5 95:4,22 96:21 97:6 98:3 102:19 103:4,21 107:13 109:19 115:6 116:7,17 120:8 122:19,22 138:21 138:24 139:6 154:4 describing 85:25 88:10 90:5 102:25 description 52:18 69:22 80:7 88:25 96:11 99:23 100:5 100:23 104:4,9 105:2,6 107:12 119:7 124:4,6,13 124:25 125:2 127:8 131:16 138:4 147:17</p>	<p>descriptions 34:16 65:25 69:21 91:12 96:7 descriptor 111:8 design 19:21,23,25 75:20 102:6 105:15 126:16 designed 22:7 101:22 109:21 113:2 144:11 designer 93:4 designing 146:25 designs 93:5 desired 99:18 113:25 140:14 desires 125:14 desiring 120:9 detail 51:24 96:9 100:22 detailed 33:25 35:10 83:7 details 36:19 65:9 70:20 105:11 136:2 147:15 determination 136:19 determinations 135:11 determine 147:4 determined 154:14 determining 37:5 develop 32:13 60:23 developed 19:10 19:15 25:19 58:18 developing 37:18 44:12 development 32:12 42:14,20 99:24 113:3 115:2</p>	<p>device 19:16 59:17 76:17 77:23 78:9 79:13,20 95:25 96:10,14,22 97:10 97:15 98:10,24 99:4,7,9,12 101:5 101:7,15,21 102:6 102:9 104:19 106:15,16,17,20 109:21 110:15 111:2 112:25 113:3,23,24 114:25 115:5 116:6,8,14,20,22 117:6 120:3,9,20 120:22 121:3,8 122:3 123:14 126:5,15 139:15 140:6 141:22 142:4,14 143:3,24 143:25 144:2,5,6 144:11,15 145:7 147:12 154:19 156:21 devices 102:12 112:21 115:7,15 116:12 126:13,20 126:22 differ 68:18 127:10 148:21,23 difference 155:11 differences 10:4,6 10:9,25,25 11:21 88:4 133:23 different 10:2 12:24 25:21 29:22 31:21 43:15,20,21 43:22,23 44:21 59:11,13 77:14 82:21 83:13 85:20 86:11 88:2,3,6,7</p>	<p>88:11,20 89:10 104:14 111:22 113:16 116:20 125:22 143:13 149:5,10 150:7 157:10,24 difficult 28:7 direct 31:16 49:15 62:19 78:18 103:10 118:19 148:3 154:18 directed 100:8 direction 42:19 119:4 164:17 directional 103:2 directly 41:8 61:9 115:22 124:2 165:4 directs 147:21 disappointed 30:7 disappointing 30:2 disclose 34:17 102:14 disclosed 113:7 126:6 discloses 34:19 79:3 disclosure 79:24 discontinue 30:12 140:11 discuss 17:12 93:9 94:9 99:21 146:16 discussed 27:21 41:25 42:22 130:5 discussing 72:25 83:17 103:15 106:6 125:10 discussion 10:16 16:17 26:8,11 44:4 45:19 50:4</p>
--	---	---	---

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

62:17 72:16,21 73:6 86:4,25 100:10 102:23 105:8 121:7,11 137:7 157:15 disease 18:13 19:13 36:20 39:8 40:20 99:25 100:3 diseases 100:6 dismiss 58:24 dissolution 149:14 149:24 dissolve 149:4 150:10 distinct 79:3,13 distinction 14:24 district 1:15 5:7,7 5:18 16:12 18:19 18:24 36:7 56:16 doctor 17:20 161:22 doctors 131:19 document 8:20 9:9 35:6 46:2,13 47:11 48:2 86:13 87:3 105:14,16 documents 13:8 doing 61:9 62:8 120:12 159:21,22 160:4,11,22 161:18 166:7 donovan 1:12 4:4 5:1,4,16 6:1,9,15 6:19 7:1 8:1,25 9:1,17 10:1 11:1 12:1,20 13:1,13 14:1 15:1 16:1 17:1 18:1 19:1 20:1 21:1 22:1 23:1 24:1 25:1 26:1 27:1 28:1	29:1 30:1 31:1 32:1 33:1 34:1 35:1 36:1 37:1 38:1 39:1 40:1 41:1 42:1 43:1 44:1 45:1 46:1 47:1 48:1 49:1 50:1 51:1 52:1 53:1 54:1,15 55:1 56:1 57:1 58:1 59:1 60:1 61:1 62:1 63:1 64:1 65:1 66:1 67:1 68:1 69:1 70:1 71:1 72:1 73:1 74:1 75:1 76:1 77:1 78:1 79:1 80:1 81:1 82:1 83:1 84:1 85:1 86:1 87:1 88:1 89:1 90:1 91:1 92:1 93:1 94:1 95:1 96:1 97:1 98:1 99:1 100:1 101:1 102:1 103:1 104:1 105:1 106:1 106:5 107:1 108:1 109:1 110:1 111:1 112:1 113:1 114:1 115:1 116:1 117:1 118:1 119:1 120:1 121:1 122:1 123:1 124:1 125:1 126:1 127:1 128:1 129:1 130:1 131:1 132:1 133:1 134:1 135:1 136:1 137:1 138:1 139:1 140:1 141:1 142:1 143:1 144:1 145:1 146:1 147:1 148:1 149:1 150:1	151:1 152:1 153:1 154:1 155:1 156:1 156:20 157:1 158:1,7 159:1,25 160:1 161:1,4 162:1 163:7,16 dosage 26:25 27:2 37:19 112:20 153:4 dose 59:9 80:6 88:19,20,23 89:15 89:19 90:2 94:14 94:21 95:15,23 96:10,20 97:6,8 98:4 99:11,18 100:18 116:18 123:3 127:19,21 146:12 148:5,7 dosed 127:18 doses 88:24 96:20 96:24 97:2,9 99:14 dosing 86:11 88:2 88:8 89:10 100:14 101:11 125:21 126:16 double 10:13 85:3 dr 5:16 6:15 8:25 9:17 12:20 13:13 54:15 70:10,17,20 81:18,21 82:14 83:19 84:4 106:5 129:12,18,21,24 130:5,9,13,20 131:9,13,16,19,25 131:25 132:6,6 156:20 158:7 159:25 161:4 draw 151:16 drive 1:19 2:4 5:9 133:4,16	droplet 154:9,11 droplets 150:25 drs 131:19 drug 19:16 32:12 39:13 42:14,20 59:9,16,17,21 60:5 96:4,15 97:13 98:6 99:7 99:15,17 101:5 102:21 139:2,22 143:15 146:18 147:8 148:14 149:15,17,20,21 150:2,4,8,16 151:3,5 dry 96:15 due 144:3 duly 6:7,11 164:11 duration 133:6,18 134:7 141:18 e e 4:1,9 167:1 earlier 82:25 85:5 121:7 earliest 33:2,8 early 158:7 easier 26:4 easily 92:15 99:20 116:19,20 easy 22:7 34:25 112:22 128:25 159:16,22 education 36:10 effective 41:9 157:8 effectively 59:20 60:3 effects 76:7 145:4 efficacious 112:9 efficacy 66:17,24 67:11 112:19
--	---	---	---

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

<p>133:7,19 efficiency 96:11 96:19 112:12 efficiently 94:14 94:21 95:15 effort 42:16 either 11:22 15:10 22:3 30:15 33:19 62:7 64:17 69:11 83:8 110:20 114:16 115:21 elder 129:24 electronic 51:8 160:19 electronically 51:10 element 60:16 emitted 80:23 101:5,22 145:2 154:15 emitting 80:6 employee 164:24 164:25 encompass 11:20 encountered 37:13,22,23 endeavored 16:22 endeavors 21:9 ends 30:23 66:3 87:15 energy 105:3,7 enforced 61:7 english 139:10 enter 41:6 entirely 149:17 entity 39:11 equal 112:3 equate 145:13 equates 145:7 equating 12:4 79:16</p>	<p>errata 166:5,7,10 166:13 escalating 89:18 especially 27:9 134:17 152:20 esq 2:7,14,21,23 essence 70:23 97:5 102:2 152:3 essentially 34:13 57:10 61:4 116:8 130:14 establish 119:22 established 66:16 67:10 90:7 estimate 33:15 151:16 et 11:2 europe 87:20 european 85:17 87:10 88:9 89:2 89:17 90:15,21 91:11 113:12 114:4 121:15,22 evaluate 57:18 101:11,12 evaluated 44:16 55:5 80:20 131:5 136:18 evaluating 56:11 57:11 123:13 126:12 evaluation 68:5,16 68:18 event 148:5,7 everybody 40:4 52:20 69:11 100:21 113:2 evidence 54:22 95:18 124:8 125:16</p>	<p>evidenced 123:24 evolved 30:3 evolves 30:8 exact 82:3 101:9 exactly 31:2 76:10 123:8 136:18 exam 4:5,6 examination 1:13 6:13 158:4 164:10 examined 6:11 examiner 134:15 135:3,13,19,23 136:13,18 examiner's 136:23 example 26:16 71:6 100:6 124:18 125:24 154:3 156:21 examples 62:25 exclude 27:8 exh 4:11,13 exhaling 146:19 exhibit 4:10,12,14 4:15,16,17,18,19 8:18,18,21 9:10 9:15,17 13:10,15 13:16 14:5,13,19 46:3,8,9,14,19 47:12,16,17,18 48:3,7 86:14,19 89:4 121:10 exhibits 13:14 14:2 16:19 exist 61:13 expand 23:7 56:3 159:18 expect 49:23 expectation 128:3 129:6 153:20 expected 127:12</p>	<p>experience 18:4,8 71:14 123:14 159:24 161:3 experienced 58:11 experiences 18:11 55:22 147:6 experimental 88:17 expert 9:2,18 17:13,17,23 19:8 19:20,24 32:12 33:7 48:19 49:8 50:15 64:8 69:19 70:13 81:17,18 expertise 17:9 131:20 explain 15:23 explicit 115:21 118:15 explicitly 114:17 exposed 151:2,4 exposure 67:25 85:18 122:21 express 11:9 100:9 expressly 78:20 83:9 109:17 113:19 extensive 21:20 22:21 65:16 extent 18:6,9,22 38:4</p>
			f
			<p>face 33:13 35:18 36:5 37:18 70:23 fact 50:8 58:15 61:21 66:7 75:4 87:3 107:22 116:11 factor 114:10 144:24</p>

<p>factors 37:5 112:19 117:25 126:12,21 144:13 144:18,19 148:9 151:4 152:14 153:6</p> <p>facts 65:21</p> <p>fail 166:15</p> <p>fair 7:17,25 10:16 12:5 16:8 32:20 55:14 90:10 103:7 119:18 157:13</p> <p>fall 140:20</p> <p>familiar 15:2 18:12,20,25 37:16 37:22 56:8 61:3 81:21 110:5 143:20</p> <p>familiarity 21:19 38:18</p> <p>family 38:11 116:4 159:18</p> <p>far 82:21 99:23 127:23</p> <p>fashion 92:21 97:5 101:13</p> <p>fast 81:22 102:8</p> <p>fda 19:12,17 58:17 58:23 59:16 132:23</p> <p>features 120:16</p> <p>federal 1:13</p> <p>feel 11:23 50:6</p> <p>felt 25:15 64:19 69:11</p> <p>field 122:25 147:7</p> <p>fifth 2:11</p> <p>figure 22:10</p> <p>file 129:8 130:3,21 130:25 134:22 135:8,17 136:4</p>	<p>filing 35:4</p> <p>final 135:10</p> <p>find 21:10 23:8 30:14 31:15 37:25 43:4 49:3,24 50:9 51:3,13,21 58:6 59:10 64:11,22 126:20 147:16 157:19 160:24</p> <p>finding 29:5</p> <p>findings 64:6</p> <p>finish 7:15</p> <p>firm 5:23</p> <p>first 6:10 8:11,18 20:10 32:5 33:15 56:13 73:9 79:11 85:23 87:14 134:13</p> <p>fixed 78:21 138:7 138:9 139:22 140:23 144:12</p> <p>floor 2:11</p> <p>flow 144:23 145:3</p> <p>fluid 154:20</p> <p>focus 114:5</p> <p>focused 27:10 32:4 88:22</p> <p>focusing 111:15 139:8,11</p> <p>foley 2:17 6:3</p> <p>foley.com 2:22,24</p> <p>follow 22:3,25 23:4,5 38:4 69:2,8 69:9 102:4</p> <p>followed 23:10</p> <p>following 108:23 167:5,6</p> <p>follows 6:12</p> <p>footnote 70:8</p> <p>foregoing 163:8 164:14</p>	<p>forgot 28:10</p> <p>form 11:6 19:2 26:18 30:4 43:17 52:9 55:19 56:11 56:12,19 60:7,25 64:24 78:2 83:22 87:5 89:6,11 90:11 91:5,19 94:22 95:20 99:2 103:16,19 104:2,4 104:11,14 105:4 108:11 110:18 113:8 114:22 115:4,25 117:8,12 117:14 118:16 125:6 126:7 130:20,22 133:9 136:15 139:18 141:5 142:8,20 143:9 144:8 145:9 145:21 150:9 152:17 158:22</p> <p>format 72:5 161:9</p> <p>formation 103:21</p> <p>formed 55:15 80:25 97:25 98:8 104:15 144:22 147:3 154:21</p> <p>forming 104:25 130:18</p> <p>forms 26:25 27:2 37:19 112:20 155:3</p> <p>formulate 134:8</p> <p>formulation 74:2 102:21 149:12 157:4</p> <p>formulations 157:6</p> <p>forth 24:21 33:18 38:22 65:9,25</p>	<p>69:7 71:8 91:9 92:14 103:3,22 126:17 142:17 160:14</p> <p>found 11:2 48:23 49:12,25 50:4,22 65:5 136:13 157:23</p> <p>four 22:18 23:13 27:20 45:4 47:24 48:11,13 73:24 74:11,18,23 75:6 75:12 76:21 77:3 77:11 82:16,20,24</p> <p>fourth 82:10,11</p> <p>free 60:14,23 127:17</p> <p>freedom 60:21 61:4</p> <p>freely 61:17</p> <p>frequency 133:5 133:17</p> <p>frequently 21:5 25:3 38:3 96:23</p> <p>front 7:11 13:4,18 16:19 31:22 137:9 160:10</p> <p>full 6:18 29:19 30:21</p> <p>fully 90:8</p> <p>function 109:17 154:19</p> <p>funding 62:7</p> <p>further 29:18 30:2 36:19 55:24 65:24 84:16 98:20 103:4 111:12 158:3 161:23</p> <p>future 120:10 128:14</p>
--	---	--	--

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

<p>g</p> <p>gained 64:6</p> <p>ganz 69:7</p> <p>gas 102:20 103:13 103:19,22,23 104:10,11,16</p> <p>gear 54:3</p> <p>gears 93:13</p> <p>general 27:5 53:21 94:19 139:10</p> <p>generate 143:4,6</p> <p>generated 78:21</p> <p>generates 95:4 103:12 143:24</p> <p>generation 141:23 141:24 142:5,6,16 142:16,18,18,19 142:19 143:5,18</p> <p>generic 20:7,16</p> <p>generous 69:20</p> <p>germany's 68:17</p> <p>getting 39:13 49:21</p> <p>ghofrani 45:5 47:20,20 50:16 51:2 52:4 54:21 63:16,22 81:10,12 84:16,22 85:8,15 85:22 86:4,21 87:10 88:21 89:3 89:14,25 90:4,8 90:14 91:3,8,10 91:15 123:20 134:18</p> <p>ghofrani's 86:25</p> <p>giessen 61:20,25 62:3 87:2 91:14 91:16</p> <p>give 13:6 22:7 62:25 70:2 96:21 156:20</p>	<p>given 25:24 31:25 32:17 41:22 48:22 71:22 82:9,13 164:18</p> <p>gives 65:23 159:14 159:14,16</p> <p>go 7:6 11:16 13:6 24:6 27:17,25 29:5,10 39:13 49:19 50:9 56:6 78:25 82:10 93:19 93:22 96:7 117:3 137:6 150:2 158:9 160:13</p> <p>goal 66:21,22 121:2</p> <p>goals 61:11 67:8</p> <p>goes 34:18 42:16 66:25 85:22,24</p> <p>going 7:5 12:2 25:9 26:11,20,21 27:8 28:12 40:24 41:19 45:3,17,21 52:15 54:4,7,11 61:23 69:5 86:9 94:3 105:17,21,25 110:21 127:10 151:7,22 156:12 156:16 162:3</p> <p>good 5:13,22 6:15 6:16 91:17 105:19 105:20</p> <p>goodrich 2:10 5:24</p> <p>gotcha 12:3</p> <p>graphs 65:17</p> <p>great 26:24 45:13 156:8</p> <p>greater 90:18 91:2</p> <p>ground 7:5 123:16</p>	<p>grounds 63:11</p> <p>group 62:3 117:15 124:8,21 143:16 158:20 159:11,20 160:9 161:11</p> <p>groups 123:11</p> <p>guess 11:8 26:11 27:25 57:2</p> <p>guide 114:11</p> <p style="text-align: center;">h</p> <p>half 134:5 160:18</p> <p>halolite 147:15</p> <p>halolite's 147:11</p> <p>halted 41:11</p> <p>hand 165:8</p> <p>handed 9:15 13:14 46:7,18,25 47:17 86:18</p> <p>handing 8:17</p> <p>happen 27:3 59:6 59:14</p> <p>happened 26:16</p> <p>happening 68:25 97:21 138:12,16</p> <p>happens 59:7 87:19</p> <p>hard 50:7 71:8 72:7 81:23 82:25 83:3 160:17</p> <p>header 57:2,4,8</p> <p>heading 43:9</p> <p>heard 36:8 73:4</p> <p>heart 64:17 75:17 85:17 87:10,20 88:9 89:2,17 90:16,22 91:11 113:12 114:4 121:15,22 122:22</p> <p>held 5:8 152:3</p> <p>help 56:6</p>	<p>helpful 11:11 28:21,22 29:2</p> <p>helps 31:16</p> <p>hereto 165:4</p> <p>hereunto 165:8</p> <p>herz 52:4 81:12,24 82:12 83:7</p> <p>high 41:2</p> <p>higher 157:4</p> <p>highly 148:13</p> <p>histories 129:9 130:3,21 135:9 136:4</p> <p>history 33:22 92:10 130:25 134:22 135:17</p> <p>home 118:11</p> <p>homes 128:24</p> <p>honest 42:13</p> <p>hope 160:5</p> <p>horst 35:18,22</p> <p>hour 8:4,5 54:4 93:15,22</p> <p>hours 11:17,18 75:10</p> <p>house 25:4,16 26:7</p> <p>human 68:16,17 68:21 111:25 112:18 114:9 117:24 126:12,13 126:21 154:24</p> <p>hypertension 17:24 18:3,8,12 18:17 19:8 26:13 31:14 32:2,6,14 39:6,23 40:6 64:21 66:18,25 67:12 73:11 76:3 76:13 77:2 88:18 99:22 100:11 108:22 120:18</p>
--	---	--	--

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

<p>131:21 132:2,8 133:25 hypothesis 30:9 30:11</p>	<p>101:3 118:11 123:4 126:14 improve 116:21 117:25 122:15 124:11 126:14,15 126:15,20,21 128:6,11 improved 117:23 122:9 improvements 27:2 117:20,24 122:7,16 128:22 improving 126:13 include 38:23 50:3 64:19 89:4 115:13 133:5,17 137:16 143:17 included 16:17 57:3 65:18 66:13 69:8 75:2 77:15 88:25 102:17 124:12 125:12 includes 70:22 90:25 136:22 137:13 including 112:24 inconsistency 88:6 incorrect 74:15,24 157:18 increase 89:19 97:14 independent 15:25 34:7 62:6 index 81:23 indexed 28:18 29:3 71:10,15 indicate 32:5 54:20 58:10 64:4 70:4 71:21 81:11 92:5 116:14,18 127:4 128:2</p>	<p>138:14 indicated 24:9 59:19 86:6 98:5 119:15 148:15 indicates 62:4 72:2 127:17 138:9 139:4 141:17 indicating 31:25 indication 113:20 indicator 109:15 109:20 110:8,25 111:10,19 112:5 129:5 indicators 112:24 indicia 53:18 56:18 57:4,12,20 58:2,6 132:17 136:24 indirectly 154:13 154:18 165:5 individual 11:12 28:4 69:14 95:24 98:13 99:19 individuals 36:8 36:11 61:11,20,24 inertia 57:15 influence 151:5 influenced 28:5 inform 161:15 information 10:18 10:23 18:14 22:21 26:5 27:6 30:25 33:9,12 34:11 38:14 39:2 51:17 52:19 53:4,11 56:11 57:21 58:7 64:16 65:8,16,17 66:4 69:24 73:17 75:2 77:15,17 82:14 85:12,12,17 87:20 88:14 90:14</p>	<p>90:15,17,20,24 91:20 98:16 117:12 119:4 124:6 125:3 127:14,17 158:19 161:17 inhalable 59:21 60:5,23 61:21 inhalation 36:18 37:16,19,24 41:20 42:8 55:25 73:23 74:17,19,23 75:5 77:5,19 78:12,14 88:23 89:5,16,21 90:3,18 91:2 97:13,17 98:7 99:8,10,11 101:19 101:25 110:2 115:2 120:23 122:21 123:7 133:24 143:21 144:13,18 148:21 150:21 153:16 155:6 156:21 inhalations 75:12 77:3 134:10 inhale 80:25 95:24 97:11,16 101:17 101:24 102:3,8 110:16 111:3 141:21 144:21 145:15 inhaled 64:15 66:18 67:12 79:9 85:15 103:20 112:20 132:8 151:19 152:16,21 152:25 153:2,7 154:22,24 inhaler 97:23 146:7</p>
<p>i</p>			
<p>i.e. 103:13 idea 27:11 34:22 42:17 ideas 26:25 42:22 42:23,24 identification 8:22 9:11 13:11 46:4 46:15 47:13 48:4 86:15 identified 22:23 33:20 34:17 36:16 40:14 55:7 69:5 identify 5:11 30:13,16 33:13 34:25 56:7 78:8 115:12,19,21 119:25 152:7 157:16 idiopathic 76:25 ii 109:2,10 111:9 121:15 122:13,18 123:24 124:2,15 125:4,9,10,23 126:4 illinois 1:19 2:5 3:23 5:9 164:6 165:9 immediate 64:6 immediately 22:3 82:5 107:5 150:5 impact 148:9 149:20 imperative 166:12 implied 111:12 important 7:6 11:21 14:12 17:11</p>			

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

<p>inhales 99:7 102:8 initial 40:13 74:10 87:2 102:18 initially 22:3 40:11 44:13 innovation 42:18 innovations 41:17 41:23,24 42:11 inserted 75:17 insoluble 150:9 inspiratory 144:23 145:3 instance 140:19 instituted 63:10 123:16 instruct 16:6 instructed 80:24 instructions 99:5 106:22 166:1 integer 97:14 intended 91:10 96:24 100:7 102:10 103:20 111:11,20 intending 150:15 inter 51:5 interacted 92:12 interaction 99:4 interactions 25:20 126:22 interdisciplinary 25:25 interest 64:6 69:13 158:11,21 159:19 interested 22:11 26:22 31:13 53:2 53:3 64:14 158:21 159:11,21 160:6,7 160:25 161:11 165:4</p>	<p>interface 126:13 155:13 interference 128:17 intermittent 141:23 142:5,15 international 23:18 159:3 interpretation 108:5 111:9 112:4 interpretations 43:20 interpreting 39:2 interval 127:22 138:19,22 interventions 40:11,17 invented 34:2 invention 34:8,16 35:6 99:25 102:19 102:24 104:9,16 105:12,15 114:20 118:7 inventors 34:2,8 35:2,15,17,21,25 36:2,14 investigate 60:23 investigated 64:21 investigating 39:16 investigation 67:15 investigational 68:24 69:15 investigations 68:21 113:18 investigators 117:15 122:15 124:10 125:18 127:10</p>	<p>invites 115:22 117:5 120:16 involved 16:13 18:16 40:8 53:16 60:11 69:6 112:19 113:3 involvement 18:23 ipr 1:6,7 5:19 7:2 8:19 9:2,16,18 13:15,17 17:3 31:12 46:9,25 136:7 iprs 5:19 issue 14:3 25:22 26:14 35:16 40:21 70:5,14 81:12 114:21 129:9 136:7,19 137:9 160:20 issued 136:6,10,11 136:17 137:3 issues 10:21 12:11 17:11 37:17 38:2 57:21 125:19 126:19,21 italics 84:17 item 37:12 items 11:9,12 13:24 36:24 41:15 iyer 2:23 6:3</p>	<p>70:23,23,24 71:17 72:3,8 82:4 85:17 87:11,20 88:10 89:2,17 90:16,22 91:11 113:12 114:4 121:16,22 journals 25:14,20 26:24 52:24 71:14 160:19 july 81:14 82:19 83:20 jump 28:9 june 16:11 81:12</p>
			k
			<p>k 2:11,18 keep 16:4 keeping 32:19 38:13 69:23 71:13 78:11,16 148:16 153:19 kept 93:13 key 21:20,23 22:4 22:22 23:5 53:8 146:24 kim 1:16 3:22 164:6 165:13 kit 108:21 kmathas 2:8 knew 25:10 116:9 158:19 159:21 know 7:4,21 8:7 12:3 13:2 23:10 27:12,15 28:5 29:10,10 30:6,10 34:9,13,17,21,23 35:12,14 36:10,13 36:15 37:21,25 38:3 40:2 43:5,24 48:15,24 50:10,21 52:21 53:10 58:24 59:6,14 60:17</p>

<p>61:5,13,14,14 66:7 71:17,24 72:2 79:23 85:21 85:25 96:7 97:11 101:9,18 102:8,22 105:12 113:17 128:16 129:13,20 131:15,24 132:5 132:13 135:22 138:3 151:24,24 152:9 157:11,21 158:24 160:8,23 161:14 knowing 41:4,11 49:17 57:19 117:23 knowledge 33:5 39:8 41:19 42:7 49:16 55:23 56:2 91:18 98:19 161:7 known 42:5 52:16 52:17 55:10 62:15 102:12 112:18 119:4 122:25 126:12 134:3,10 148:17,20 knows 71:9 kurt 2:7 5:13 12:13</p>	<p>lardner 2:17 6:3 lasts 141:3 latest 161:17 law 5:23 17:17 layperson's 69:22 lead 19:24 leaf 26:15 leafing 26:23 learn 65:25 learning 116:8 leave 148:22 left 34:13 leg 69:8,9 legal 16:4 61:6 length 119:16 138:18,21 139:7 level 36:11 37:6 38:25 39:20 50:12 55:8 84:9 levels 37:10 lewis 35:19,22 libraries 50:8 70:7 70:16 71:6,15 81:13,22 83:15 library 22:9,10 50:11 51:4,5,8 71:6 81:22 82:19 83:2 license 164:7 165:14 licensed 164:7 life 134:5 lifestyle 128:17 light 57:23 106:11 106:15,21 107:4 116:17 134:17 lights 116:13 limit 92:13 100:3 102:10 limitation 15:20 15:23 16:2 98:24</p>	<p>106:13 148:3 limited 61:17 123:18 line 100:17 167:8 linked 22:9 61:9 list 36:24 63:5 85:5,7 91:17 152:7 listed 14:7 35:17 35:21,24 82:9 literature 21:5 22:2,8,15,23 23:3 23:6 29:15 85:7 little 8:4 54:3,4 81:7,7 93:13 124:5 125:2 llp 2:3,17 loan 22:12 51:5 locate 48:13,15 52:2 located 61:25 long 45:9 68:3 69:8 76:7 77:25 93:4,14 98:9,12 98:17,22 101:17 130:2,24 135:8 138:14 141:7 144:21 149:2,13 150:8 longer 8:4 94:4 134:6 143:17 149:16 155:17 157:23 160:18 longest 82:25 look 22:6,25 23:21 27:17 29:10 33:12 34:11 39:15,19 50:25 53:23 56:22 57:16 58:4 65:24 70:20 82:11 84:14 87:19 91:7 95:8</p>	<p>108:20 121:17 124:7 125:9 147:9 147:14 161:18 looked 16:5 18:13 49:2,5,12 51:12 51:20 55:15,16 88:16 125:4 130:2 135:8 looking 22:19,20 22:20 23:6 27:5 43:3,8 55:5,23 83:10 87:8 89:18 100:16 137:11 138:6 losing 96:14 loss 101:7 lost 96:13,13 98:2 lot 37:25 41:5,7 42:15 55:23,24 61:3 lots 161:2 lunch 93:21,23 lung 40:25 41:5,12 62:5,9,11,13 102:2 lungs 39:25 40:12 40:14,19 100:8 101:6,8,10 120:24 121:2 149:5</p>
i			m
<p>I 1:16 3:22 164:6 165:13 labeled 84:25 108:25 laboratories 1:4 5:5,20 lack 159:4 lag 49:20 71:11 150:2 language 109:12</p>			
			<p>maebius 2:21 6:2 mailing 71:8 major 10:8 23:25 making 77:10 mangan 3:4 manifestation 40:9 manner 23:7 24:7 50:20 51:7 72:11 96:22 99:12 100:21 137:20</p>

138:2 manuscript 160:13,16 marked 4:10 8:18 8:21 9:10 13:9,15 13:20 14:19 46:3 46:8,14,19 47:12 48:3 86:14,19 market 132:22 marketplace 61:10 marks 5:3 54:12 106:2 156:17 mass 138:25 material 22:11,12 49:21 72:13 102:20 129:20 148:24,25 149:3 150:14 151:13,14 materials 26:2 28:6 37:19 38:12 39:17 41:6 42:8 70:21 71:21 mathas 2:7 4:6 5:13,14 11:6 12:16 26:18 30:4 43:17 46:23 47:7 47:10 52:9 55:19 56:19 60:7,25 64:24 78:2 83:22 87:5 89:6,11 90:11 91:5 94:22 95:20 103:16 108:11 110:18 111:5 113:8 114:22 115:25 117:8 118:16,23 120:4 121:19 125:6 126:7 130:22 133:9,20 136:15,25 139:18	140:8 141:5 142:8 142:20 143:9 144:8 145:9,21 152:17 156:4 158:5 159:23 161:22 matter 5:5 25:12 28:8 124:16 matters 94:2 164:13 maureen 1:11 4:4 5:1,4 6:1,9,19 7:1 8:1 9:1 10:1 11:1 12:1 13:1 14:1 15:1 16:1 17:1 18:1 19:1 20:1 21:1 22:1 23:1 24:1 25:1 26:1 27:1 28:1 29:1 30:1 31:1 32:1 33:1 34:1 35:1 36:1 37:1 38:1 39:1 40:1 41:1 42:1 43:1 44:1 45:1 46:1 47:1 48:1 49:1 50:1 51:1 52:1 53:1 54:1 55:1 56:1 57:1 58:1 59:1 60:1 61:1 62:1 63:1 64:1 65:1 66:1 67:1 68:1 69:1 70:1 71:1 72:1 73:1 74:1 75:1 76:1 77:1 78:1 79:1 80:1 81:1 82:1 83:1 84:1 85:1 86:1 87:1 88:1 89:1 90:1 91:1 92:1 93:1 94:1 95:1	96:1 97:1 98:1 99:1 100:1 101:1 102:1 103:1 104:1 105:1 106:1 107:1 108:1 109:1 110:1 111:1 112:1 113:1 114:1 115:1 116:1 117:1 118:1 119:1 120:1 121:1 122:1 123:1 124:1 125:1 126:1 127:1 128:1 129:1 130:1 131:1 132:1 133:1 134:1 135:1 136:1 137:1 138:1 139:1 140:1 141:1 142:1 143:1 144:1 145:1 146:1 147:1 148:1 149:1 150:1 151:1 152:1 153:1 154:1 155:1 156:1 157:1 158:1 159:1 160:1 161:1 162:1 163:7,16 mean 14:4 15:23 31:12 33:12 43:19 45:12 50:7 53:19 54:25 55:22 57:7 57:25 67:19 68:15 71:3 82:13 84:23 87:8 88:7 92:7 93:3,18 95:9 100:2 104:23 108:9 109:12 120:10 129:20 132:24 137:18 152:23 meaning 106:21 110:16 111:3,9,11 111:12,20 139:16 140:7,20 141:14 142:7,14 143:8	144:6 156:23 means 40:23 44:3 55:3 79:21 82:17 82:20 120:24 127:20 136:12 137:24 measurement 88:16 measurements 75:18 measures 67:23 68:6 88:18 mechanism 104:12,15 mechanisms 40:5 media 5:3 54:12 106:2 156:17 medical 17:19 26:23 131:19 132:2 medicament 95:5 109:23 120:23 medication 79:22 127:18 140:17 medications 127:19 medicine 26:17 101:18 meeting 24:18 26:2 29:12 64:18 72:4,6,9 161:12 161:16,20 meetings 24:19 25:5,8 41:21,25 161:10 meets 106:12 members 25:16 26:4 memory 56:23 131:3
---	--	---	---

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

<p>mention 89:14 130:9</p> <p>mentioned 15:9 15:12,12,15,18,20 23:12 158:14 159:2</p> <p>mere 124:11</p> <p>merely 117:11 124:17</p> <p>met 72:17</p> <p>method 56:14 73:10 80:13 120:22</p> <p>methodologies 103:25 104:3</p> <p>methodology 127:9</p> <p>methods 65:24 92:3 127:15</p> <p>microgram 79:7 88:22 90:18,25 154:23</p> <p>micrograms 74:2 77:7 88:13,24 89:5,16 90:2,19 91:3 153:25 154:5 154:10,11,14</p> <p>microprocessor 96:25</p> <p>mid 42:22</p> <p>mil 74:2 77:8 79:7</p> <p>miles 59:10</p> <p>milliliter 88:13</p> <p>mind 31:17,19 40:19 44:9 119:23 135:2 144:19 145:5</p> <p>minute 53:17 85:18 98:15 99:3 122:20 123:6 153:17,18</p>	<p>minutes 90:19 91:2,25 92:21,24 93:20 94:4 105:18 127:2,23 148:6</p> <p>missions 61:12</p> <p>mistaken 83:20</p> <p>mistakenly 87:18 87:24 91:18</p> <p>mode 91:24 92:6,8</p> <p>modified 92:14 103:4</p> <p>modify 113:7 114:19 115:23 117:6 120:3 121:8 122:3 125:21 126:5</p> <p>modifying 125:19</p> <p>molecular 40:5</p> <p>moment 95:3 100:18</p> <p>money 161:19</p> <p>monitored 74:20</p> <p>month 82:21</p> <p>morning 5:13,22 6:15,16</p> <p>motivated 112:8 112:15 121:8 126:19</p> <p>motivates 114:18</p> <p>motivation 112:21 113:2,7 114:6,11 115:11,18 116:16 118:6,14 119:14 119:16,22 120:2 122:3 123:23 124:22 126:4 128:22</p> <p>mouth 101:7</p> <p>mouthpiece 80:24 81:3 147:22</p>	<p>move 16:9 30:16 61:10</p> <p>moving 41:9 123:6</p> <p>multiple 20:20 21:17 146:11</p> <p>myriad 54:20</p> <p style="text-align: center;">n</p> <p>n 4:1,9</p> <p>n.w. 2:18</p> <p>name 5:23 6:18</p> <p>named 159:15</p> <p>names 45:7,14</p> <p>natash 6:2</p> <p>natasha 2:23</p> <p>national 24:18 25:5,7</p> <p>nature 25:25</p> <p>near 42:3</p> <p>nebulization 123:7</p> <p>nebulized 89:20 92:13 147:8</p> <p>nebulizer 19:23 58:12,18,22 59:4 59:7,11,13 73:25 75:9 77:6 78:14 78:17,21 79:8,10 79:19 80:3,4,11 80:15 81:2 85:19 88:11 91:23 92:10 92:19 95:4 102:15 103:13,15,19 104:7,13,19,20,23 107:14,20 109:2,7 111:23 112:10 113:7,16 116:4 117:17,17,18,21 118:9,11 122:7,17 122:20,24 123:2,4 123:5,9 125:15 127:20 137:14,17</p>	<p>137:19,24,25 138:5 139:13,16 139:21,24 140:4,7 140:13,21 141:2,4 142:24 143:14 145:2,24,25 146:18,22 147:12 147:14,19 157:2,7</p> <p>nebulizers 19:21 80:18 102:17 104:2,9,13 113:14 117:22 118:3 122:9 125:19 146:25,25 153:14 156:24</p> <p>nebutech 73:25</p> <p>necessarily 28:4 34:10,25 57:15 58:3 120:10 136:12</p> <p>necessary 16:7 96:3 166:4</p> <p>need 8:5 11:23 13:5 22:12 25:17 30:13 39:7 40:24 43:25 56:8,10 59:9 68:22 109:17 118:10,18 119:3,9 120:25 121:12 123:25 124:14 125:9,23 126:3 129:3,14 131:2 143:15 152:3,10 152:19 157:24</p> <p>needed 50:6 51:5 51:16,18 69:11 96:23 113:17 123:3</p> <p>needing 39:7 50:12 120:8</p>
--	--	--	---

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

needs 97:14,22 101:17 102:11 negotiation 25:13 neither 88:24 104:18 never 19:4 96:16 new 5:7 26:25,25 41:23 42:22,23 49:21 71:17 niyer 2:24 non 57:5,12 76:12 96:14 136:13 143:17 noon 93:19 normally 83:14 notary 163:24 notation 155:21 note 5:17 14:12 noted 14:18 166:10 notice 9:25 14:10 14:21 novel 160:5 number 4:10 5:4 10:4 11:8 14:5,13 14:14 20:3 25:20 25:21 28:25 30:20 42:6 46:9 47:2,6 54:13 61:25 65:5 68:23 69:3 76:17 82:15,20 85:13,13 85:20 86:2,22 87:9,9 88:3 96:24 97:2,3 106:3 110:11 134:9 138:24 143:13 151:10,21 152:2 153:2,4 154:13 156:18 164:8 numbered 36:24 41:15 86:5	numbers 10:3 14:7,16 numeral 109:10 111:8 nw 2:11 o oath 7:10 16:22 object 11:6 26:18 30:4 43:17 52:9 55:19 56:19 60:7 60:25 64:24 78:2 83:22 87:5 89:6 89:11 90:11 91:5 94:22 95:20 103:16 108:11 110:18 113:8 114:22 115:25 117:8 118:16 125:6 126:7 130:22 133:9 136:15 139:18 141:5 142:8,20 143:9 144:8 145:9 145:21 152:17 objection 111:5 133:20 136:25 140:8 158:22 objective 53:18 56:17 57:4,11,12 57:14,20 58:2,5 132:17 136:23 observable 132:10 observations 83:6 observed 68:7 75:10 obtain 51:13,22 83:10,15 obtained 83:14 obtaining 51:7 obvious 32:3 39:24 57:24 62:22	63:4,15,21 72:18 88:4 112:22 113:13 124:17 136:13 144:20 obviously 10:2 136:5 obviousness 55:5 55:16 57:5,6,12 57:14 62:18 123:19 occur 148:17 occurrence 127:7 occurring 87:15 october 70:5,25 71:5 offer 155:10 offers 159:5,9 office 1:2 165:9 oh 14:4 107:14 okay 7:22 8:8 10:8 10:14,24 11:15 12:8,12 13:3,22 13:24 14:9,17,25 15:19 16:8 18:15 21:16 23:12 24:13 27:20 28:9,18 29:16 31:2,23 32:15,20 33:24 35:8,15 36:23 38:6 39:4,22 42:25 44:6,20,25 44:25 45:16 47:7 47:23 48:18 50:14 51:19 52:15 55:11 56:16,25 57:25 58:9 60:20 63:5 66:7 69:25 71:20 72:14,25 73:21 74:14 75:4 79:16 81:6 83:5 86:24 88:5 89:24 90:6	90:24 91:22 93:6 93:7 94:6,7 95:8 95:11 103:6 104:18 106:10,18 107:2 108:3,18,24 110:6,24 111:15 112:6 113:5 114:3 115:17 119:21 120:14 121:17,25 123:15 124:23 126:24 127:24 129:23 131:18 133:3 135:12 139:8 141:22 143:3,25 145:19 146:6 150:22 151:17 152:8 153:23 156:2 157:13 158:2,24 161:24 olschewski 35:18 35:22 once 99:10 ones 7:6 45:10 online 21:25 72:6 72:10 81:14,24 82:2,5 83:3,7 158:15 open 93:23 95:3 113:23 117:19 120:19 122:6 opening 56:18,22 openly 103:3 opens 103:3 operate 61:17 92:20 operating 80:5 operation 92:19 107:5 operator 98:13
---	---	---	--

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

<p>opinion 11:3,10 11:13 12:24 24:3 33:8 42:10 48:19 49:9 50:15 56:12 56:12 60:2 62:20 63:3,14,18,20 66:15 67:9 70:13 79:2 81:17,21 94:12,19 95:13 97:7 100:13 106:10 109:16 110:6,13,24 111:17 123:22 130:20 131:8 139:12 140:3,25 145:6 151:25</p> <p>opinions 31:7 44:8 44:13,16 53:14 54:24 55:13,16,18 73:20 124:16 130:19 136:23</p> <p>opportunity 65:24 86:9 96:2 102:4 117:20 122:6 123:13 134:6 159:6,10</p> <p>optical 129:4</p> <p>optineb 77:6 78:13,17 79:8,19 80:2 88:11 92:9 92:19 116:4 122:19,24 127:20</p> <p>opto 106:13,17,19 106:23,24 107:11 107:21,24 109:3,8 109:18,20 111:24 116:6</p> <p>order 55:21 125:21 126:14</p> <p>ordinary 24:4 26:9 27:23 31:7</p>	<p>31:10 32:22 48:20 49:10 50:18 51:25 109:13 114:18</p> <p>organization 26:2</p> <p>organizations 24:18 25:2</p> <p>organs 40:7</p> <p>original 51:14,22 52:12 105:15 166:12</p> <p>outcome 88:18 165:5</p> <p>outpatient 118:3</p> <p>output 79:20 139:14 140:4</p> <p>outside 18:4 58:23 59:20 60:4,9,22 67:6 69:16</p> <p>overcome 54:21 55:9 57:5,17,22</p> <p>overlap 12:9</p> <p>owner 1:8 2:25 5:25 6:4 20:11 43:15 158:8</p> <p>owner's 135:4,14</p> <p>owns 22:10</p>	<p>papers 21:4 23:8 65:5 66:13,14</p> <p>paradigm 42:24</p> <p>paragraph 31:17 31:17,24 32:4,24 32:25 36:23 41:14 43:7,10 53:23 54:17,19 55:12 57:3,11 58:9 62:19 64:4 69:25 71:21 72:15,20 73:5,8,21 75:25 78:19,24,25 79:12 81:10,11 84:14,15 87:13,22 90:20 94:16 95:2,3,9,10 100:17 103:10 104:22 112:6 114:6 127:25 130:8,15 134:12 134:14,25 147:17 156:3</p> <p>paragraphs 32:18 44:10 73:15 108:23 146:14 147:10</p> <p>part 24:21 32:5 34:22 40:18 71:20 74:20,21 75:25 102:5,12 123:23 132:20 136:4 145:16 155:18,24 161:16</p> <p>particle 152:25 153:4,15 154:17</p> <p>particular 23:2,5 24:20 25:2,18,25 26:6 27:6,21 29:11 31:11,12 32:9 35:10 38:2 39:10 40:18 41:20</p>	<p>41:25 44:4 48:16 48:23 49:4 51:18 52:4 53:2 55:21 56:5 65:9 66:2 67:7 69:24 70:22 76:14 92:22 100:3 100:4 101:2,12 114:12 115:9 134:22,25 138:25 143:15 157:3 158:10,19 159:11 159:20 160:9,19</p> <p>particularly 23:9 134:4</p> <p>parties 16:13 18:5 18:20,24 36:7 164:25 165:2</p> <p>patent 1:2,3,8 2:25 5:25 6:4 9:3 9:19 10:10,11,14 12:22,25 16:2 20:3 33:3 34:20 35:4,14,21,25 36:19 43:14 50:21 52:17 53:15 54:23 55:8 62:18,21 63:9,15,20,21 102:22 105:14 108:16,20 109:6 111:16,18,21 116:11 120:21 123:18,21 135:4 135:14 136:10,10 136:18 137:12,12 138:6 153:11 158:8</p> <p>patents 13:7,25 14:3 15:3,6 16:18 32:11 33:13,17 34:3,12 35:16 36:3,17 40:4</p>
	p		
	<p>p.m. 105:22,24,24 106:3 156:13,15 156:15,18 162:4,6</p> <p>page 4:3 7:7 9:7 9:23 10:2 14:14 14:15 56:25 62:16 70:23 96:8,8 163:13 167:8</p> <p>pages 10:15 33:13 35:18 36:5 163:9</p> <p>pah 77:2</p> <p>pan 29:18</p> <p>paper 51:14,22 64:7 66:5,9 91:17</p>		

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

44:22 59:20 60:3 60:10,12,18 83:18 107:10,22 108:4 114:21 124:17 126:11 129:9 136:6 137:9,23 147:25 148:2,4 153:22,25 pathology 39:25 40:15 patient 58:16 69:14 89:16 96:4 96:17 97:14,22 99:6 101:17 102:3 110:14,15 111:2,2 112:25 113:25 116:19,22 117:23 120:24 122:9 123:3,5 126:21 132:7,10 134:3 143:16 144:3,13 144:18,21,24 146:19 147:2 155:5,7 patient's 59:7 99:4 144:3 patients 58:10,21 59:3 66:24 67:3,4 67:20 68:2,3,8 69:10 73:23 74:7 74:7,9,10,13,16 74:22 75:4,8,11 75:14 76:11,18,25 77:10,22,24 78:10 78:16 79:9 85:19 85:21,23 88:3,15 89:22 90:2 92:12 112:23 116:14 118:2,9 128:15,20 128:23 131:20 143:16 155:16,18	155:19,22,24 patton 45:5 48:9 50:17,23 63:16,22 93:8 94:9,13,20 95:14,18,22,25 96:6,16,21 97:8 98:10,17,21 99:6 99:21 100:10,13 100:23,23 101:16 101:20 102:14,17 103:11,14,20 104:6,17,20 105:2 105:6,9 106:6,11 109:17,19 114:18 115:3,6,22 116:7 116:9,10,17 120:15,19 121:3 123:20 128:5 patton's 96:6,18 97:10 99:23 104:3 104:9 112:10 114:7 129:3 pause 97:24 98:7,9 138:11,15 145:17 147:2,20 peak 148:5,10,10 148:12,19 149:11 151:7,9,20 152:15 153:6 peer 28:14 pending 8:10 people 27:17 28:22 62:2 64:13 65:23 81:3 131:22 159:16,19 160:5,7 160:22,25 161:7 161:18 perfect 12:12 perfectly 51:11 perform 21:5	performing 21:8 23:23 24:6 26:10 35:9 perfused 41:2 period 68:4 80:22 89:21 93:5 138:14 141:10 143:6,18 periodical 26:14 26:16 periods 141:23 142:5,15 147:20 147:20 permit 43:6 person 24:4,5 26:9 26:21 27:24 31:7 31:10 32:22 34:25 43:2 48:20 49:10 50:18 51:25 68:24 69:18,19 80:24 93:25 102:8 109:12 114:18 person's 154:25 personal 18:11 164:17 personally 48:13 persons 27:22 pertaining 1:15 pertinent 10:21 160:8 petitioner 1:5 2:9 5:15 ph.d. 1:12 4:4 5:1 6:1,9 7:1 8:1 9:1 10:1 11:1 12:1 13:1 14:1 15:1 16:1 17:1 18:1 19:1 20:1 21:1 22:1 23:1 24:1 25:1 26:1 27:1 28:1 29:1 30:1 31:1 32:1 33:1	34:1 35:1 36:1 37:1 38:1 39:1 40:1 41:1 42:1 43:1 44:1 45:1 46:1 47:1 48:1 49:1 50:1 51:1 52:1 53:1 54:1 55:1 56:1 57:1 58:1 59:1 60:1 61:1 62:1 63:1 64:1 65:1 66:1 67:1 68:1 69:1 70:1 71:1 72:1 73:1 74:1 75:1 76:1 77:1 78:1 79:1 80:1 81:1 82:1 83:1 84:1 85:1 86:1 87:1 88:1 89:1 90:1 91:1 92:1 93:1 94:1 95:1 96:1 97:1 98:1 99:1 100:1 101:1 102:1 103:1 104:1 105:1 106:1 107:1 108:1 109:1 110:1 111:1 112:1 113:1 114:1 115:1 116:1 117:1 118:1 119:1 120:1 121:1 122:1 123:1 124:1 125:1 126:1 127:1 128:1 129:1 130:1 131:1 132:1 133:1 134:1 135:1 136:1 137:1 138:1 139:1 140:1 141:1 142:1 143:1 144:1 145:1 146:1 147:1 148:1 149:1 150:1 151:1 152:1 153:1 154:1 155:1 156:1
---	--	---	---

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

<p>157:1 158:1 159:1 160:1 161:1 162:1 163:7,16</p> <p>pharmaceutical 23:18 37:14 159:3</p> <p>pharmaceutically 138:8 154:6</p> <p>pharmaceuticals 5:15 26:22</p> <p>pharmaceutics 17:14 26:23</p> <p>phrase 73:9 111:21,22 112:2 137:17,23 159:4</p> <p>physical 28:24 116:5</p> <p>physically 161:15</p> <p>physicians 132:14</p> <p>pick 26:13</p> <p>piece 22:22 23:2,5</p> <p>pieces 38:14 66:12</p> <p>place 22:5 30:25 35:7 44:2,3 64:3 95:23 97:16 99:2 164:21</p> <p>placed 43:4 72:23 96:10 97:2 109:23</p> <p>plasma 148:5,10 148:12,19 149:11 151:7,9,20 152:15 153:6</p> <p>please 5:11 6:6,18 7:20 8:6 13:2 142:3 166:3,7</p> <p>plethora 57:20</p> <p>plus 155:19</p> <p>point 30:3 40:2 42:18 46:23 70:18 81:19 95:17 117:4 130:19</p>	<p>pointed 32:21 94:25</p> <p>points 63:6</p> <p>poon 64:7</p> <p>popular 27:22</p> <p>populations 41:2</p> <p>portion 67:21 74:20 87:13 134:22</p> <p>portions 115:5 157:17</p> <p>posa 31:25 32:5 32:11 33:4 38:23 41:11 42:25 43:5 43:9,11,16,21,24 44:8,9,15,19,21 53:2 55:10 62:22 63:4 65:7 77:12 80:3,7,9 87:17 92:2 109:15 112:3 112:7,15 114:10 114:24 115:11,18 115:23 116:3,8 117:5 118:18 119:3,9,13,17,23 120:11,16,24,25 121:8 125:17 126:9 127:6,17 128:2,10 129:5 137:17 153:20</p> <p>posa's 98:19 126:18 146:10</p> <p>posas 28:8 110:11</p> <p>possibility 58:25 145:25</p> <p>possible 44:15 103:2 112:23 118:8 128:25 139:4 146:21</p> <p>post 24:23,23</p>	<p>potential 26:25</p> <p>potentially 39:11 60:13 102:10 115:9</p> <p>powder 96:15</p> <p>power 105:3,7,9</p> <p>preamble 72:17 72:21 73:6</p> <p>precede 32:18</p> <p>precedes 86:3</p> <p>precisely 94:14,21 95:15</p> <p>precision 96:9 100:18,20 112:11</p> <p>predetermined 102:19</p> <p>prefer 152:13</p> <p>preference 28:4</p> <p>preferred 134:3</p> <p>preliminary 29:17 29:25 67:8</p> <p>preparation 157:16</p> <p>prepare 99:9</p> <p>prescribed 61:17</p> <p>preselected 95:5</p> <p>present 2:2 3:2 25:3 150:14 159:25 160:21 161:16</p> <p>presentation 24:24 28:16,17,24 29:9 72:4</p> <p>presentations 24:17 41:22 161:4</p> <p>presented 24:12 26:3 29:25 54:22 64:16 101:13 117:13 150:4 161:10,17,21</p>	<p>presenting 160:9</p> <p>press 71:25 72:9</p> <p>pretty 22:20 40:24 41:9 65:6 86:8 92:15 159:19</p> <p>prevent 8:14</p> <p>previous 25:11 44:13 160:24 164:9</p> <p>previously 17:8</p> <p>primarily 67:17 103:20 105:16</p> <p>primary 146:17 147:5</p> <p>principles 80:5</p> <p>print 82:7</p> <p>printed 147:24</p> <p>prior 18:4 36:6 45:2 53:12 55:9 55:15,24 56:4 57:13 62:23 63:7 83:16</p> <p>priority 33:2,9,21 40:3 83:17 126:10</p> <p>probably 8:3 11:10 17:11 21:17 21:19 22:16,16 23:19 27:7,10 29:22 49:14 68:18 71:7 82:16,17,24 82:25 146:23</p> <p>problem 36:13 37:22 100:19</p> <p>problems 37:12 37:23 38:7 39:5</p> <p>procedure 1:14</p> <p>proceeding 7:2 9:16 13:16,17 14:14,24 16:14 24:5 56:17</p>
--	---	--	--

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

<p>proceedings 5:19 12:15,17 14:22 17:12 31:13 46:9 46:19 47:18 48:8 86:19 136:8 164:19 process 22:2 158:25 produced 92:11 96:12 141:9,11 155:14 produces 147:21 148:5 producing 91:24 product 59:21 60:5 134:10 production 140:12 products 19:11 58:8 133:24 professional 18:3 18:8,11 19:2 20:20 progression 18:14 prolific 65:6 promising 76:8,9 prosecution 54:23 55:7 prostacyclins 19:5 38:8,10 protocol 69:9,16 protocols 68:22 provide 88:14 89:20 95:18 118:7 118:7,9 151:25 provided 9:2,18 10:18 31:6 33:10 33:12 48:12,14,16 55:17 62:7 69:3 70:21 72:5 89:15 98:17 100:22 123:14 125:15</p>	<p>129:21 provides 95:25 97:8,9 100:5 113:6 120:2,22 134:5,6 providing 8:14 48:18 49:8 50:14 153:15 public 163:24 publication 21:6 24:23 29:5 30:22 51:2,18 65:11,15 66:5,6,9 85:18 160:17 161:9 publications 20:21 24:20 29:2 50:21 50:23 52:17 65:7 82:7 159:15,17 publicly 48:20,25 48:25 49:9 50:18 52:18,22 publish 21:4 published 19:4 24:10,12,16 29:16 29:24 50:2 65:4 70:6,15,25 71:3 81:13 82:22 83:4 90:21 91:19 160:14 161:5,14 publisher 25:23 26:6 82:6 publishers 25:12 25:13,22 publishing 21:13 21:18 24:14,21 27:18 pubmed 23:17 159:2 puff 146:7,9 pulmonary 17:23 18:3,7,12,17 19:8</p>	<p>26:13 31:14 32:2 32:6,13 39:6,23 40:5,21,23 64:21 66:18,24 67:12,22 68:5 73:11 75:16 76:3,13,25 88:17 99:22 100:2,10 101:2 108:22 113:3 120:17 131:21 132:2,7 133:24,24 134:4 148:17 pulse 78:21 80:12 81:5 92:24 93:4,5 97:5 98:4 112:2 112:10 117:18 138:10 139:7,9 141:14 145:7,20 146:9,11 pulsed 73:24 77:6 78:13,17 79:8,19 80:2,4,11,14 92:4 92:6,8 94:13,20 95:15,19 96:19 97:5,8 98:4 99:12 107:13,19 109:2,6 111:23 122:23 137:7,14,17,20,22 137:24 138:2,4 139:12,15,24 140:6,20 141:4,11 141:24 142:6,13 142:23 143:7 144:6,15 145:7,23 146:17,22,25 147:12,19 156:22 156:25 157:8 pulses 79:3,13,16 79:19 99:20 140:15,17 141:19</p>	<p>purpose 24:14 25:6 113:16 146:17,22 147:5 purposes 146:24 pursuant 1:13 pursue 51:5 61:21 pursued 30:20 pursuing 59:21 60:5 put 27:13 34:7 71:10 127:13 143:5 putting 25:7</p> <hr/> <p style="text-align: center;">q</p> <hr/> <p>qualify 42:21 qualities 115:12 115:19 quantitative 88:4 question 7:16,24 8:10,11 11:22 27:3 29:23 31:19 31:21 34:5 49:7 52:11 73:3,4 78:5 95:12 101:4 103:6 115:20 117:2 118:21,22,24 119:12 123:17,19 133:11 152:4,9,20 questions 7:14,20 11:17,18 12:21 16:23 28:11 125:11,25 158:3,6 158:9 161:23,25 queue 160:18 quite 37:16,21 38:13 67:4 129:10 160:15 quote 54:20 73:10 74:22 76:22 84:15 137:14</p>
--	---	---	--

r	83:12 166:5 167:10,12,14,16 167:18,20 reasonable 69:22 93:20 128:2 reasons 161:2 167:6 recall 16:10 20:9 53:9 56:21 59:23 66:11 105:10 108:14 121:11 122:10 129:11,17 129:19,21,23 131:15 135:6 158:12,16 recalled 130:4 receipt 166:14 receive 68:24 75:5 79:22 96:3,5 received 58:16 67:21 69:2 71:7 73:23 74:11,17,19 74:22 75:8,11,15 76:12,20 77:2,14 88:15 155:22,23 receiving 68:9 75:21 99:13 127:21 recess 54:9 105:23 156:14 recognize 45:11 46:10,20 47:19 48:8 recognized 44:15 52:5,23,24 recollection 36:9 42:4 65:3 85:4,16 100:12 101:20 102:16 135:25 record 5:3,16 6:18 9:14 13:15 45:18	45:20,22 47:3,9 54:8,12 105:22 106:2 122:14 135:18 156:13,17 162:4 164:18 reduced 134:9 164:16 reducing 123:2 refer 14:16 46:11 46:21 61:23 62:2 63:25 64:3 68:11 74:6 77:4 82:14 120:21 121:14 126:3 reference 10:10 45:4,5,5,6 46:11 46:21 47:21 48:9 48:19 50:16,17,17 52:2,4 63:25 64:23 65:11,19 73:13 85:6,14 86:5,21,21,24 89:25 90:7,9 91:23 117:5,6 120:15 121:10,13 121:18 122:5,12 references 21:20 21:24 22:4,25 45:3 48:11,13 50:16 63:24 89:3 93:9 94:9 112:16 114:17 119:14,24 123:23 referred 66:14 82:12 83:11 114:3 121:9 122:4 referring 14:15 45:8,9 62:3 74:7 79:11 81:4 122:13 refers 128:4	refresh 56:22 131:2 regarding 32:10 37:23,24 40:21 43:22 44:3,4 56:3 56:4 71:14 81:21 105:11 125:19 131:25 132:6 138:18 152:20 regardless 21:23 144:12,17 regimen 77:14 125:21 129:2 region 39:25 40:9 40:15,15 regions 115:9 regular 27:4 regulations 68:20 rehash 17:10 reinhale 96:23 97:18 rejected 134:15 135:3,13,20,23 rejections 135:10 136:2,3 relate 153:25 related 12:6 18:16 relationship 62:14 157:10 relative 82:7 164:23,25 relatively 123:12 127:22 release 71:25 72:9 relevant 21:10 33:5 64:12,22 reliability 112:11 reload 96:22 rely 10:9 65:20 70:19 73:16 124:14 125:23
----------	---	--	---

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

<p>relying 70:17 81:18</p> <p>remained 67:6 68:3</p> <p>remaining 138:4</p> <p>remember 82:3 102:25 125:14 135:9</p> <p>remind 129:15</p> <p>reminded 121:12</p> <p>repeat 73:2 142:3</p> <p>repeated 96:2</p> <p>repetition 96:20 97:6,9</p> <p>replace 57:17</p> <p>report 32:19 50:13 56:18,22 129:14 131:17 135:19</p> <p>reported 3:22 64:14 67:24 98:21 164:15</p> <p>reporter 1:17 6:6 7:14 9:15 13:14 107:16 121:5 149:7 159:7 164:4 164:7</p> <p>reports 11:9 59:24</p> <p>represent 47:9 70:9</p> <p>representing 5:25 6:4</p> <p>reproducibility 100:25 101:3</p> <p>reproducible 118:10 141:8</p> <p>request 22:12</p> <p>requested 67:5 69:11</p> <p>require 107:10 109:6 145:7</p>	<p>required 140:14</p> <p>requirement 107:24 137:13 141:18 145:6</p> <p>requirements 16:5 61:4 68:17 102:11 146:2</p> <p>requires 30:13</p> <p>requiring 138:6</p> <p>reread 133:14</p> <p>research 21:5,9 24:6 26:10 29:19 30:3,7,19 38:5 61:21 124:21 159:11 160:2</p> <p>researched 18:2,7</p> <p>researcher 158:20</p> <p>researchers 158:20 159:25</p> <p>researching 158:10</p> <p>reside 119:17</p> <p>resident 30:23</p> <p>resistance 40:22 67:22</p> <p>resistant 68:6</p> <p>respect 37:12 38:8 39:5 41:16 44:21 63:19 111:17 135:22 136:23</p> <p>respiratory 154:16</p> <p>response 98:11 157:7</p> <p>responses 132:7 132:11 135:10 136:3,3</p> <p>responsibility 35:3</p> <p>rest 15:10 57:13 66:25 71:18</p>	<p>107:22 108:6</p> <p>restart 31:20</p> <p>restate 110:20 133:11</p> <p>result 30:10 115:10 155:10</p> <p>resulted 30:22 66:8</p> <p>return 166:12</p> <p>returning 41:14</p> <p>review 20:23 22:23 23:8 64:8 64:20 84:11 86:9 130:17 135:17 160:13</p> <p>reviewed 16:25 17:6 28:14,17 86:6 129:8 130:25</p> <p>reviewing 42:3 129:11,17,23</p> <p>right 30:17 43:8 45:15 57:19 67:18 74:15 75:18 81:9 107:11 109:18 115:24 121:25 148:7 152:11</p> <p>rise 57:22</p> <p>robert 35:18,20,22 35:24</p> <p>rom 72:5,12</p> <p>roman 109:10 111:8</p> <p>romanette 108:25</p> <p>rosati 2:10 5:24</p> <p>roscigno 35:19,22</p> <p>rose 50:12</p> <p>routines 75:23</p> <p>royalty 60:13</p> <p>rubin 35:19,23 129:12 130:13 131:9,19,25 132:6</p>	<p>rubin's 130:5,9,20</p> <p>rules 1:14 7:5</p> <p>rulings 43:21</p> <p>running 158:15</p> <p>rx 62:5,9,11,14</p> <p style="text-align: center;">s</p> <p>s 2:14</p> <p>safe 67:3</p> <p>safety 66:16,23 67:11</p> <p>sales 133:4,16</p> <p>salt 138:9 154:6</p> <p>saw 29:9 64:15</p> <p>saying 57:10 104:6,8</p> <p>says 57:4 58:14 76:10,22,24 146:20</p> <p>schmehl 35:19,23</p> <p>science 23:22 49:5 49:18 50:9 58:8 159:2,13</p> <p>scientific 158:10</p> <p>scientist 37:15</p> <p>scientists 161:11</p> <p>scifinder 23:20</p> <p>scott 70:10</p> <p>seal 165:8</p> <p>search 22:2,18 23:7,24 27:14,16 29:15 49:16 50:4 50:21 82:2 159:6 159:10,12,22</p> <p>searchable 28:19 53:7,12 57:15 58:3</p> <p>searches 22:15 29:8 158:15</p> <p>searching 26:12 28:2 53:10 159:20</p>
---	---	---	--

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

<p>second 14:23 73:22 99:11 107:15</p> <p>secondary 54:22 55:3,6,17 56:5 134:16 135:5,14 135:20</p> <p>seconds 98:25 99:8 141:3 146:8</p> <p>section 22:21 57:3 72:16 73:14 85:14 87:22 88:21 90:19 91:12 108:25 135:7</p> <p>see 14:4 27:17 37:2 43:25 50:25 55:18 58:13,14 62:24 64:9 70:11 74:4 76:4,5 79:14 79:15 81:15,16 84:19,20 108:21 112:13 117:16 127:3 128:8,9 129:15 134:19,20 141:16 146:16,20</p> <p>seeger 35:20,23</p> <p>seek 128:10</p> <p>seeks 128:6</p> <p>seen 44:2 66:10 71:25 86:7 157:20</p> <p>select 26:6 113:15</p> <p>selecting 113:23</p> <p>selective 134:5</p> <p>sending 81:2</p> <p>sense 77:21</p> <p>sensory 116:21</p> <p>sent 128:23</p> <p>sentence 64:5 73:22 75:3 86:3 87:14 95:9 119:24 119:25 120:7,15</p>	<p>127:25 134:14 135:3</p> <p>sentences 91:14</p> <p>separate 99:14,14 99:16,17</p> <p>sequence 135:9 139:3</p> <p>sequential 97:18</p> <p>serial 56:14</p> <p>series 82:22 97:11 113:17</p> <p>serious 100:19</p> <p>served 25:15</p> <p>session 93:14</p> <p>set 36:2 88:2,8 106:25 118:9 119:23 137:8 165:8</p> <p>setting 118:4,4</p> <p>seven 11:17,17</p> <p>severe 66:24</p> <p>sheet 166:6,7,10 166:13</p> <p>shelf 71:10</p> <p>shelved 71:18</p> <p>shelves 71:16</p> <p>shoot 94:6</p> <p>short 124:4,24 127:22</p> <p>shortage 133:2</p> <p>shorter 31:18 133:6,18</p> <p>shorthand 1:17 32:9 164:4,7</p> <p>shortly 49:25</p> <p>show 29:7,14</p> <p>showing 57:6</p> <p>shown 163:12</p> <p>side 41:4</p> <p>sign 166:7</p>	<p>signal 110:14</p> <p>signaled 147:14</p> <p>signals 106:16</p> <p>signature 9:7,23 165:12 167:23</p> <p>significant 18:6 41:23 42:6 57:23 155:11</p> <p>significantly 127:10 155:8,9</p> <p>signing 166:9</p> <p>silent 76:17</p> <p>similar 23:24 24:6 33:14 38:7,10 39:17 103:24 117:14,15 123:12 148:20 161:18</p> <p>similarity 104:12</p> <p>similarly 15:14</p> <p>simply 70:17 80:10 128:5</p> <p>single 41:12 58:16 75:15 89:15,25 101:25 122:23 123:16 127:21 148:4,7</p> <p>site 148:14 150:18</p> <p>sitting 82:13 152:11</p> <p>situations 128:24 150:7</p> <p>six 15:11,11 49:20 82:24 85:13,14,18 86:2,5,22 87:9,10 90:7,14,16 91:25 92:21,24 122:20 123:6 127:2,23</p> <p>sixes 87:16</p> <p>size 152:25 153:4 153:15 154:9,11 154:17</p>	<p>skill 24:4 26:9 27:23 31:7,11 32:22 37:6 38:25 48:21 49:10 50:19 51:25 109:13 114:19</p> <p>slightly 69:20 155:12</p> <p>smaebius 2:22</p> <p>society 23:21</p> <p>sold 132:22</p> <p>solubility 149:19 150:12</p> <p>solution 77:7 79:7 88:12 89:21 96:15 143:15 149:2,17 149:22 150:3,5 152:24</p> <p>solve 36:14</p> <p>somebody 34:19 38:25 53:2 59:12 60:9 139:3</p> <p>somewhat 25:24 32:8,16 36:16 63:12 157:4</p> <p>sonsini 2:10 5:24</p> <p>soon 83:3</p> <p>sorry 28:9 70:2 86:23 107:17,19 121:21 144:4 149:10,11 159:7,9</p> <p>sort 10:25 11:25 12:3 21:17 23:7 31:18 35:5 38:18 42:2 56:7 71:17 146:7,10 151:16 157:10 158:24</p> <p>sorts 30:18</p> <p>sound 104:24 106:12,16,21 107:4 116:17</p>
---	---	--	--

<p>129:4 sounds 116:13 source 51:8 90:17 104:24,24 105:3,7 sources 21:10 space 42:17 166:5 speak 12:10 28:7 129:14 130:16 speaking 21:11,12 21:12 94:18 100:17 123:18 139:10 speaks 37:15 specific 12:21 34:4 34:21,22,23 38:14 58:12,18 62:23,25 73:15 94:25 97:12 97:12 99:25 109:25 113:6,10 116:10,11 118:19 119:4 120:6,14 124:2 125:12 131:3 135:7 139:7 144:19 151:14 152:19 153:12,12 specifically 36:12 38:7 39:5 43:25 62:19 66:12 83:24 100:10 108:15 119:6 127:4 specification 36:20 108:14 specified 146:3 164:22 specify 102:11 spectrum 40:25 speed 102:7 spent 157:11 sponsor 24:19 ss 163:3</p>	<p>stabilities 38:22 stage 115:14 stand 59:16 135:12 standard 146:7 standards 61:7 standpoint 19:2 65:19 117:25 start 8:17 21:23 27:7 30:10 31:24 39:16 55:25 62:17 72:19 122:13 127:8 144:4 started 21:13 54:16 81:4 94:8 125:10 starting 21:25 32:23 72:15,20 73:5 91:15 starts 87:14 151:11 state 1:17 6:17 18:13 36:21 39:8 62:20 70:2 73:22 76:2 78:20 103:11 112:7 113:19 134:14 163:2 164:6 166:4 stated 51:19 65:21 78:23 107:21 109:10 111:7 124:19 statement 55:2 66:21 74:14 76:10 113:5 114:5,16 115:21 117:4 120:15 134:23 135:13 statements 32:25 124:3 125:12</p>	<p>states 1:2,14 20:16 35:14 68:19,21 74:21 stating 84:15 stenographically 164:15 step 11:11 stephen 2:21 6:2 steps 21:9 51:24 sterritt 35:20,24 strategies 89:10 94:13,20 95:14 101:11 126:16 strategy 86:11 88:19,20 strawn 2:3 5:14 stream 91:24 141:3 street 2:11,18 strike 72:18 82:16 88:6 89:8 strong 57:5 structure 38:15 students 30:23 studies 120:10 study 29:19 65:9 66:2,8,12,16,22 67:7,10,18,21 68:10 69:6,17 74:10,20 75:20,24 76:14 77:20 84:17 85:10,20,21,23 87:14,21 89:13,19 89:22 92:22 128:19 155:20 subject 53:8 163:11 166:9 submit 28:16 submitted 19:11 19:17</p>	<p>subscribed 163:20 subscriber 71:7 subscribers 71:5 subscribes 51:9 subsequently 101:8 subset 73:9 74:12 subsidiary 62:12 substance 157:22 substitute 111:10 111:18 success 58:6,7 128:3 successful 128:6 128:12,14,19 132:18 sufficed 73:17 sufficient 77:16 suggests 119:8 suite 1:18 2:18 sulica 64:7 summarize 130:14 summary 102:18 supplement 29:11 72:8 125:4 support 73:20 supported 62:5 90:8 91:3 suppose 25:9 supposed 59:8 96:4 sure 7:7 8:12 21:21 29:21 38:17 49:6 69:18 73:3,5 86:8 104:5 129:25 130:15 142:4 147:18 157:2 surface 150:25 151:3 surrounding 114:25</p>
--	---	--	---

suspect 58:20 59:2 59:12 157:3 suspension 148:25 149:3,12,15 swan 69:7 swear 6:6 switch 139:14 140:5,11,15,16 switches 142:17 switching 140:12 140:12 sworn 6:8,11 163:20 164:11 synchronize 111:25 synonym 109:14 110:10,12 synonymous 110:8 system 41:13 98:2 101:12 102:6 103:5,12 118:11 153:20 157:3 systems 37:17,18 t t 167:1 table 13:25 tail 55:11 take 8:3,5,11 21:10 22:4 51:25 54:5 56:22 93:16 93:21 94:15 98:22 119:4 121:17 129:3 139:3,5 146:6,7,8 152:6 156:5,8 taken 1:13,16 127:6 164:21 takes 98:18,25 99:8,10	talk 36:20 45:2 53:17 81:6 86:10 94:8 96:8 105:9 talked 17:8 60:20 105:18 106:6 155:15 talking 12:25 27:18 44:22 84:23 84:24 106:8 115:14 127:24 150:20 152:21 talks 88:22 89:25 target 39:9,10,22 39:24 40:24 targets 39:12,14 40:8,13 tasked 35:9 taught 104:20 teach 76:3 104:7 teaches 94:13,20 95:14,18 100:14 103:12 106:11 109:17 teaching 97:8 101:16 112:9 129:4 147:7 teachings 54:20 62:22 112:11 114:7,7,12 115:3 115:23 134:18 technologies 42:5 80:20 technology 115:4 tell 69:20 97:23 122:14 telling 49:11 tells 62:5 64:13 70:24 72:9 76:20 79:25 117:19 122:5	ten 99:8 141:3 term 69:8 76:7 77:25 109:25 110:11 111:12 137:18 143:20 155:17 terminologies 16:5 terminology 78:15 79:12 80:10 108:15 139:11 142:2 terms 16:6 27:16 test 75:13 77:4 155:23,25 testified 6:11 20:2 20:6,15 89:24 119:15 testify 7:9 164:12 testimony 11:19 16:16 17:2,6 83:5 84:7,12 86:25 114:9,13 116:25 119:13,19 122:10 163:9 164:18 text 118:15,19 thank 14:10 31:5 47:7,10 146:15 156:11 161:22 162:2 thanks 161:24 therapeutic 27:6 39:10,18 40:11,16 112:19 129:2 therapeutically 112:9 128:14 therapeutics 1:7 5:6,21 60:3,4 62:12,15 therapies 64:20 110:2 148:21	therapy 32:13 60:24 64:8 67:6 67:20 68:3 69:12 117:23 118:12 122:9 123:2,4,5,7 124:11 143:22 thesis 30:24 thing 8:9 34:23 126:14 things 13:20 30:18 31:3 38:2,17 41:10 55:25 56:7 56:9,13 59:6,14 69:3 85:24 93:25 97:3 116:13 124:10 131:4 152:3 153:2 160:4 161:2,10,18 think 11:10 15:22 20:10 21:14 23:9 25:21,22 26:3 27:22 32:8,18 35:2 36:21 41:18 43:6,25 46:25 47:9 57:9,18 60:9 67:7 69:21 74:12 82:15 84:8 90:6 90:13 91:9 92:18 93:25 100:5,15,22 106:6 108:13 109:14 111:7 113:20 121:12 129:19 130:13,15 131:22 145:11,15 147:15 151:22,23 152:5,9,19 157:24 thinking 124:7,10 125:3,18 157:12 thirty 166:13 thomas 35:19,23
---	---	--	---

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

<p>thought 73:4 130:7</p> <p>thoughts 125:14</p> <p>three 22:17 50:15 63:5,11 73:19,23 74:17,19,22 75:5 75:9,15 76:21 77:7,11 79:3,9,13 122:23 123:7 126:25 127:5,21 140:17</p> <p>time 5:10 8:6 16:21 17:5 23:20 24:25 30:16,17 33:6 39:3,20,21 42:3,5,9 44:3 45:22 49:21 51:12 54:8,13 67:19,25 68:4 69:4 71:7,10 79:21 80:21,21,22 80:22 81:2 88:16 91:16 93:21 97:22 101:14,21 102:13 105:19,20,22 106:3 112:17 113:4 115:13,20 123:3 126:10 127:22 130:2,24 132:25 133:6,18 135:8 138:11,14 138:15,19,22 139:4,7 141:8,10 141:17,18 142:11 143:6 144:22 148:10,12,15,19 149:10 150:2 151:9,20 152:6,15 153:6 156:8,13,18 157:7,10,12 158:3 160:6,17 161:19 162:2,4 164:21</p>	<p>timed 141:2</p> <p>timeframe 127:5 140:13 153:18,19</p> <p>timeframes 123:13</p> <p>times 6:23,24 20:3 22:22 24:15,19,22 28:5,20 29:7 66:4 68:23 71:8,17 73:24 74:11,18,23 75:6 76:21 77:11 96:3 97:21 98:6 124:5 125:2 148:16</p> <p>timing 35:14 153:5</p> <p>tissue 40:25</p> <p>tissues 41:7,10</p> <p>titled 5:20</p> <p>titles 36:16</p> <p>tmax 149:6,10,16 149:20,22,25 150:6,11,22 151:8 151:25 153:19</p> <p>today 5:19 7:9 8:15 11:19 17:10 45:3 157:15,16</p> <p>told 82:2 122:4 131:22</p> <p>tolerability 66:17 66:23 67:11</p> <p>tolerated 67:3</p> <p>top 13:25</p> <p>topic 53:13,14 158:21 159:22</p> <p>topics 54:3 56:5 160:8</p> <p>total 139:5 154:21 155:20</p> <p>track 16:4 93:14</p>	<p>tracked 132:25</p> <p>tract 154:16</p> <p>trademark 1:2</p> <p>traditional 80:13 80:16 104:2,13,19 157:5</p> <p>transcript 12:15 12:17 163:11 164:15 166:14,15</p> <p>transferable 116:19</p> <p>translated 51:16</p> <p>translation 47:20 48:16</p> <p>tre 77:3,5,7</p> <p>treat 32:6,13 77:21,24</p> <p>treated 77:11,25 85:23 155:16,20</p> <p>treating 26:13 66:17 67:12 73:11 99:22 108:22 131:20</p> <p>treatment 17:23 19:12 31:13 32:2 39:6,9,23 61:22 68:9,14 69:9,13 73:24 74:11,17,19 74:23 75:8,9,15 75:22 76:3,7,13 76:21 77:3,14 112:10 113:25 120:17,25 121:2 128:6,11,13,15,16 128:19 132:2,7 133:6,18 155:23</p> <p>treatments 18:13 39:18 75:5 89:4 100:7</p> <p>treprostinil 15:5,8 15:12,14,18,20</p>	<p>18:25 36:18 38:15 59:22 60:6,24 61:22 64:15 66:19 67:13 74:3 77:19 79:6 85:15 88:12 89:20 132:8 134:4 134:8 138:8 139:2 140:23 148:6 151:20 152:16,21 153:7,13 154:2,5 154:8</p> <p>trial 1:3 20:6,15 63:10,10 123:17</p> <p>trials 18:16 87:2 91:13,13,18</p> <p>tried 47:9</p> <p>trigger 106:13,19 106:23,24 107:11 107:21,24 108:9 108:14 109:3,8,11 109:18,24 110:7 110:16 111:3,11 111:13,17,19,24 112:4 116:6</p> <p>true 21:7 163:10 164:17</p> <p>truth 164:12</p> <p>truthful 8:15</p> <p>truthfully 7:9 16:23</p> <p>try 12:22 34:7 112:21 115:11,12 115:19 126:19</p> <p>trying 11:16 12:2 20:9 21:21 31:3 35:8 43:4 45:13 57:18 61:9 72:23 100:19 114:5,15 119:21</p> <p>turn 54:16 72:14 81:9 139:14 140:5</p>
--	---	---	--

<p>146:13 156:2 turned 143:3,4,5 turning 140:10 two 5:19 9:25 10:4 11:3 12:4,6 13:14 13:21,24,25 14:2 15:6,11,11 16:18 26:15 31:12 35:16 44:22 68:2,8 69:10 74:12,16 75:10,11 76:11,18 76:25 77:10,24 78:9,16 83:18 87:16 88:3 89:9 99:13,14,16,17,20 112:16 113:21 114:16 119:14 125:23 128:20 132:14 137:9 140:15 147:25 150:6 155:15,18 155:19,22 160:23 type 147:14 types 31:3 37:12 38:7 39:5 typewriting 164:16 typical 92:18 101:23 typically 14:16 22:18 41:21 53:13 61:6,7 65:7 68:21 104:10 127:12 typos 157:19 tyvaso 18:21 58:11,16 59:4,8 59:15 132:17,21 133:4,16,23,25 134:5,8,10</p>	<p style="text-align: center;">u</p> <p>u.s. 5:7 ultrasonic 73:25 75:9 80:11,14 102:15,17 103:5 104:20,24 105:3,3 105:7,9,13 107:13 107:20 109:2,7 111:23 122:24 137:14,17,19,24 137:24 138:5 139:13,16,20,24 140:4,6,21 141:2 141:4 142:24 143:14 144:14,15 145:23 153:13 156:24 ultrasound 77:6 78:13,17 79:8,19 80:2,4,19 88:11 91:23 92:9,19 105:13 122:20 127:20 understand 7:5,8 7:19 10:3 33:17 37:4 40:4 45:8 53:19 61:16 70:2 70:5 77:18 78:4 81:11 87:7,8,17 103:14 104:5 114:8,13,15 115:17 116:25 119:11,12 126:4 127:12 130:11 132:19 133:22 134:15 137:4,18 understanding 16:2 19:23 35:5 38:24 53:21 59:18 68:16,19 75:19 125:5 135:18</p>	<p>137:21 141:25 146:11 147:7 understands 115:7 understood 7:24 84:8 115:3 124:21 126:9 130:9 160:22 underwent 155:25 undissolved 149:3 unfortunately 147:23 uninterrupted 141:2 united 1:2,7,14 5:6,21 20:15 35:14 60:3,4 62:12,15 68:18,20 university 61:20 usage 109:20 use 11:19 16:6 28:3 36:22 45:7 45:13 58:17,22 59:8,13 61:5 67:5 69:15,19,23 73:20 74:13 75:12 77:6 77:17,20 78:10,12 78:13,15 79:12 80:10,14 83:15 97:4,15 99:5,25 100:3,6 101:11,24 103:5,15 104:2,7 106:7,11 110:10 110:11,12 112:23 112:25 116:14,22 118:2 120:16,20 122:19 123:13 124:17 126:15 128:16,21 137:14 139:9,11,14 140:5 141:25 153:13</p>	<p>155:22 156:22 usefulness 118:2 user 79:21 97:11 101:24 106:16,22 123:14 126:15 155:14 users 134:3 uses 90:15 103:19 104:4 144:14 usually 99:15 102:20 103:22 160:5 ut 59:19 60:22 utc 58:18 59:21 60:10,13 utilize 96:21 119:5 utilized 39:19 121:4 145:14 utilizing 38:5</p> <p style="text-align: center;">v</p> <p>v 5:21 vaguely 62:13 129:13 valuable 23:10 valve 102:6 variety 27:11 various 37:10 88:17 vascarrunz 2:15 vascular 67:22 68:5 vasculature 40:22 40:23 venials 41:3 ventavis 133:7,19 veronica 2:14 5:23 118:23 156:4 version 82:8 92:10 versions 43:23 versus 5:6 146:11 160:23</p>
--	--	---	---

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

<p>videographer 3:4 5:2 6:5 45:17,21 54:7,11 105:21,25 156:12,16 162:3 videotaped 1:11 view 43:15 62:22 63:16,21 123:20 viewed 106:24 139:23 virtue 38:11 viscosity 157:4 vocabulary 27:15 77:18 volume 82:10,11 101:23,23 102:2,4 102:20 103:22 150:17,23,24 154:15,21,21 voswinckel 35:20 35:24 45:4 46:11 48:19 49:9 53:7 54:21 61:24 63:16 63:21,25 64:4,14 64:17,23 65:4 66:8,16,21 67:10 67:17 70:6,15,21 73:14,18 74:8,10 76:2,8,12,16,20 78:8,20 79:2,5,24 79:25 84:18,21,25 85:6,12 86:12,20 87:4,10 90:9 91:22 113:6,14,22 114:17 115:22 117:5,10 118:5,15 120:2,3,7 121:9 121:10,13,15 122:3,5,13,18,21 123:11,19,24,25 124:3,15,23 125:4 125:9,10,12,23</p>	<p>126:4,5,24 127:4 128:5 134:18 155:16 voswinckel's 64:5 66:11 112:8 114:7 vs 1:6</p> <p style="text-align: center;">w</p> <p>wacker 1:18 2:4 5:9 wait 7:15 107:16 146:8 149:7 walking 75:22 want 11:16 22:24 23:10 27:14 34:16 42:15 43:24 53:17 81:9 93:16 97:23 106:23 120:21 137:6 160:3,10 wanted 60:11 139:3 washington 2:12 2:19 5:24 6:3 wasting 92:13 146:18 water 157:5 watson 1:4 5:5,15 5:20 way 26:24 29:22 31:4 57:9,19 58:19 59:25 62:8 103:8,18 108:19 109:21 110:9 112:16 117:3,7 127:19 157:25 ways 102:23 114:12 126:20 143:13 web 23:22 49:5,18 50:9 58:8 159:2 159:13</p>	<p>website 25:5,8,17 26:5 week 49:20 71:11 83:21 84:7,12 weeks 82:24 went 54:15 83:10 werner 35:19,23 west 1:18 2:4 5:9 whereof 165:7 widely 71:4 willing 51:11,20 82:12 willingness 122:15 wilson 2:10 5:24 winston 2:3 5:14 winston.com 2:8 wish 167:5 wished 31:25 32:6 wishing 32:13 withdraw 78:7 witness 1:12 4:3 5:16 6:6,7,10 11:7 26:19 30:5 43:18 52:14 55:20 56:20 60:8 61:2 65:2 78:3 83:23 87:6 89:12 90:12 91:6 94:23 95:21 103:17 107:18 108:12 110:19 111:6 113:9 114:23 116:2 117:9 118:17 119:2 120:5 125:7 126:8 130:23 133:10,21 136:16 137:2 139:19 140:9 141:6 142:9 142:21 143:10 144:9 145:10,22 149:9 152:18</p>	<p>156:10 158:23 159:8 161:24 163:8 164:11,11 165:7 166:1 167:23 wonder 157:20 word 15:19 53:8 105:13 108:9 109:11,15,24 110:7,10 111:10 111:13,17,18,20 112:4 137:7,22 139:9,12 157:21 wording 11:2 96:18 125:15 words 27:13 94:25 124:12 work 17:3 21:13 25:24 30:13,15,21 30:23 37:25 42:15 60:13,17 61:8 62:4,6,8 85:25 98:21 119:8 124:4 124:25 159:22 160:11 161:7 workings 102:24 works 26:12 66:11 69:21 world 42:14 100:25 write 160:12 writer 65:20 108:16 writing 160:16 written 74:15 75:7 94:17 100:23 124:12 wrong 91:19 wrote 135:3,19 wsgr.com 2:15</p>
--	--	---	--

David Feldman Worldwide

800-642-1099

A Veritext Company

www.veritext.com

x
x 4:1,9
y
yeah 21:3 42:23 43:19 78:4 85:8 86:7 156:7
year 16:11 29:12 72:11 81:25 82:3 160:17
years 26:15 38:13 82:4 160:23
yep 74:5
yesterday 17:7
z
zamanian 129:18 129:21 131:13,19 131:25 132:6
zamanian's 131:16

Federal Rules of Civil Procedure

Rule 30

(e) Review By the Witness; Changes.

(1) Review; Statement of Changes. On request by the deponent or a party before the deposition is completed, the deponent must be allowed 30 days after being notified by the officer that the transcript or recording is available in which:

(A) to review the transcript or recording; and
(B) if there are changes in form or substance, to sign a statement listing the changes and the reasons for making them.

(2) Changes Indicated in the Officer's Certificate. The officer must note in the certificate prescribed by Rule 30(f)(1) whether a review was requested and, if so, must attach any changes the deponent makes during the 30-day period.

DISCLAIMER: THE FOREGOING FEDERAL PROCEDURE RULES ARE PROVIDED FOR INFORMATIONAL PURPOSES ONLY. THE ABOVE RULES ARE CURRENT AS OF SEPTEMBER 1, 2016. PLEASE REFER TO THE APPLICABLE FEDERAL RULES OF CIVIL PROCEDURE FOR UP-TO-DATE INFORMATION.

VERITEXT LEGAL SOLUTIONS
COMPANY CERTIFICATE AND DISCLOSURE STATEMENT

Veritext Legal Solutions represents that the foregoing transcript is a true, correct and complete transcript of the colloquies, questions and answers as submitted by the court reporter. Veritext Legal Solutions further represents that the attached exhibits, if any, are true, correct and complete documents as submitted by the court reporter and/or attorneys in relation to this deposition and that the documents were processed in accordance with our litigation support and production standards.

Veritext Legal Solutions is committed to maintaining the confidentiality of client and witness information, in accordance with the regulations promulgated under the Health Insurance Portability and Accountability Act (HIPAA), as amended with respect to protected health information and the Gramm-Leach-Bliley Act, as amended, with respect to Personally Identifiable Information (PII). Physical transcripts and exhibits are managed under strict facility and personnel access controls. Electronic files of documents are stored in encrypted form and are transmitted in an encrypted fashion to authenticated parties who are permitted to access the material. Our data is hosted in a Tier 4 SSAE 16 certified facility.

Veritext Legal Solutions complies with all federal and State regulations with respect to the provision of court reporting services, and maintains its neutrality and independence regardless of relationship or the financial outcome of any litigation. Veritext requires adherence to the foregoing professional and ethical standards from all of its subcontractors in their independent contractor agreements.

Inquiries about Veritext Legal Solutions' confidentiality and security policies and practices should be directed to Veritext's Client Services Associates indicated on the cover of this document or at www.veritext.com.